ZA200400161B - Novel vinyl carboxylic acid derivatives and their use as antidiabetics etc. - Google Patents

Novel vinyl carboxylic acid derivatives and their use as antidiabetics etc. Download PDF

Info

Publication number
ZA200400161B
ZA200400161B ZA200400161A ZA200400161A ZA200400161B ZA 200400161 B ZA200400161 B ZA 200400161B ZA 200400161 A ZA200400161 A ZA 200400161A ZA 200400161 A ZA200400161 A ZA 200400161A ZA 200400161 B ZA200400161 B ZA 200400161B
Authority
ZA
South Africa
Prior art keywords
phenyl
allyloxy
bis
acetic acid
chloro
Prior art date
Application number
ZA200400161A
Inventor
Lone Jeppesen
Bury Paul Stanley
Mogensen John Patrick
Ingrid Petterson
Per Sauerberg
Original Assignee
Novo Nordisk As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk As filed Critical Novo Nordisk As
Publication of ZA200400161B publication Critical patent/ZA200400161B/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/38—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D307/40—Radicals substituted by oxygen atoms
    • C07D307/42—Singly bound oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00—Carboxylic acid nitriles
    • C07C255/49—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C255/54—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing cyano groups and etherified hydroxy groups bound to the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/40—Unsaturated compounds
    • C07C59/58—Unsaturated compounds containing ether groups, groups, groups, or groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/66—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety
    • C07C69/73—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of unsaturated acids
    • C07C69/734—Ethers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D277/24—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
    • C07D333/14—Radicals substituted by singly bound hetero atoms other than halogen
    • C07D333/16—Radicals substituted by singly bound hetero atoms other than halogen by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2603/00—Systems containing at least three condensed rings
    • C07C2603/02—Ortho- or ortho- and peri-condensed systems
    • C07C2603/04—Ortho- or ortho- and peri-condensed systems containing three rings
    • C07C2603/06—Ortho- or ortho- and peri-condensed systems containing three rings containing at least one ring with less than six ring members
    • C07C2603/10—Ortho- or ortho- and peri-condensed systems containing three rings containing at least one ring with less than six ring members containing five-membered rings
    • C07C2603/12—Ortho- or ortho- and peri-condensed systems containing three rings containing at least one ring with less than six ring members containing five-membered rings only one five-membered ring
    • C07C2603/18—Fluorenes; Hydrogenated fluorenes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Child & Adolescent Psychology (AREA)
  • Psychiatry (AREA)
  • Endocrinology (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Thiazole And Isothizaole Compounds (AREA)

Description

NOVEL VINYL CARBOXYLIC ACID DERIVATIVES AND THEIR USE AS ANTIDIABETICS—ETC
FIELD OF THE INVENTION
The present invention relates to novel vinyl carboxylic acid derivatives, to the use of these compounds as pharmaceutical compositions, to pharmaceutical compositions compris- ing the compounds and to a method of treatment employing these compounds and composi- tions. More specifically, the compounds of the invention can be utilised in the treatment and/or prevention of conditions mediated by the Peroxisome Proliferator-Activated Receptors (PPAR), in particular the PPARS suptype.
BACKGROUND OF THE INVENTION
Coronary artery disease (CAD) is the major cause of death in Type 2 diabetic and metabolic syndrome patients (i.e. patients that fall within the ‘deadly quartet’ category of im- paired glucose tolerance, insulin resistance, hypertriglyceridaemia and/or obesity).
The hypolipidaemic fibrates and antidiabetic thiazolidinediones separately display moderately effective triglyceride-lowering activities although they are neither potent nor effi- cacious enough to be a single therapy of choice for the dyslipidaemia often observed in Type ’ 2 diabetic or metabolic syndrome patients. The thiazolidinediones also potently lower circu- lating glucose levels of Type 2 diabetic animal models and humans. However, the fibrate class of compounds are without beneficial effects on glycaemia. Studies on the molecular actions of these compounds indicate that thiazolidinediones and fibrates exert their action by activating distinct transcription factors of the peroxisome proliferator activated receptor - (PPAR) family, resulting in increased and decreased expression of specific enzymes and apolipoproteins respectively, both key-players in regulation of plasma triglyceride content.
Fibrates, on the one hand, are PPARa activators, acting primarily in the liver. Thiazolidin- ediones, on the other hand, are high affinity ligands for PPARYy acting primarily on adipose tissue.
Adipose tissue plays a central role in lipid homeostasis and the maintenance of energy balance in vertebrates. Adipocytes store energy in the form of triglycerides during periods of nutritional affluence and release it in the form of free fatty acids at times of nutritional deprivation. The development of white adipose tissue is the result of a continuous differentiation process throughout life. Much evidence points to the central role of PPARY activation in initiating and regulating this cell differentiation. Several highly specialised proteins are induced during adipocyte differentiation, most of them being involved in lipid storage and metabolism. The exact link from activation of PPARy to changes in glucose metabolism, most notably a decrease in insulin resistance in muscle, has not yet been clarified. A possible link is via free fatty acids such that activation of PPARy induces
Lipoprotein Lipase (LPL), Fatty Acid Transport Protein (FATP) and Acyl-CoA Synthetase (ACS) in adipose tissue but not in muscle tissue. This, in turn, reduces the concentration of free fatty acids in plasma dramatically, and due to substrate competition at the cellular level, skeletal muscle and other tissues with high metabolic rates eventually switch from fatty acid oxidation to glucose oxidation with decreased insulin resistance as a consequence.
PPAR. is involved in stimulating p-oxidation of fatty acids. in rodents, a PPARa- mediated change in the expression of genes involved in fatty acid metabolism lies at the basis of the phenomenon of peroxisome proliferation, a pleiotropic cellular response, mainly limited to liver and kidney and which can lead to hepatocarcinogenesis in rodents. The phenomenon of peroxisome proliferation is not seen in man. In addition to its role in peroxisome proliferation in rodents, PPAR is also involved in the control of HDL cholesterol levels in rodents and humans. This effect is, at least partially, based on a PPARa-mediated transcriptional regulation of the major HDL apolipoproteins, apo A-l and apo A-ll. The . hypotriglyceridemic action of fibrates and fatty acids also involves PPARa and can be } summarised as follows: (I) an increased lipolysis and clearance of remnant particles, due to changes in lipoprotein lipase and apo C-lil levels, (ll) a stimulation of cellular fatty acid uptake and their subsequent conversion to acyl-CoA derivatives by the induction of fatty acid binding protein and acyl-CoA synthase, (lil) an induction of fatty acid B-oxidation pathways, (IV) a reduction in fatty acid and triglyceride synthesis, and finally (V) a decrease in VLDL production. Hence, both enhanced catabolism of triglyceride-rich particles as well as reduced secretion of VLDL particles constitutes mechanisms that contribute to the hypolipidemic effect of fibrates.
PPARS activation was initially reported not to be involved in modulation of glucose or triglyceride levels. (Berger et al., j. Biol. Chem. , 1999, Vol 274, pp. 6718-6725). Later it has been shown that PPARS activation leads to increased levels of HDL cholesterol in dbldb mice (Leibowitz et al. FEBS letters 2000, 473, 333-336). Further, a PPARS agonist when : dosed to insulin-resistant middle-aged obese rhesus monkeys caused a dramitic dose- dependent rise in serum HDL cholesterol while lowering the levels of small dense LDL, fasting triglycerides and fasting insulin (Oliver et al. PNAS 2001, 98, 5306-5311). The same paper also showed that PPARS activation increased the reverse cholesterol transporter ATP- binding cassette A1 and induced apolipoprotein A1-specific cholesterol efflux. Taken together these observations suggest that PPARS activation is useful in the treatment and prevention of cardiovascular diseases and conditions including atherosclerosis, hypertriglyceridemia, and mixed dyslipidaemia (PCT publication WO 01/00603 (Chao et al.).
A number of compounds have been reported to be useful in the treatment of hyper- glycemia, hyperlipidemia and hypercholesterolemia (U.S. Pat. 5,306,726, PCT Publications nos. W091/19702, WO 95/03038, WO 96/04260, WO 94/13650, WO 94/01420, WO 97/36579, WO 97/25042, WO 95/17394, WO 99/08501, WO 99/19313, WO 99/16758 and
WO 01/00803).
Glucose lowering as a single approach does not overcome the macrovascular com- plications associated with Type 2 diabetes and metabolic syndrome. Novel treatments of
Type 2 diabetes and metabolic syndrome must therefore aim at lowering both the overt hy- pertriglyceridaemia associated with these syndromes as well as alleviation of hyperglycae- mia.
This indicate that research for compounds displaying various degree of PPAR,
PPARy and PPARS activation should lead to the discovery of efficacious triglyceride and/or . cholesterol and/or glucose lowering drugs that have great potential in the treatment of dis- eases such as type 2 diabetes, dyslipidemia, syndrome X (including the metabolic syndrome i.e. impaired glucose tolerance, insulin resistance, hypertrigyceridaemia and/or obesity), cardiovascular diseases (including atherosclerosis) and hypercholesteremia.
In EP 98 690 the following vinyl carboxylic acid derivatives has been described as thromboxane A2 synthetase inhibitors:
RS G—cH— CH—O0—f J—(CHy),—COOR’ rR> 2 wherein R'is pyridyl, R? is phenyl, thienyl, furyl, naphtyl, benzothienyl or pyridyl, and
R? is hydrogen or lower alkyl. in WO 00/64888 diaryl acid derivatives and their pharmaceutical compositions are described as PPAR receptor ligands.
DEFINITIONS | }
In the structural formulas given herein and throughout the present specification the following terms have the indicated meaning:
The term "C,.c-alkyl" as used herein, alone or in combination, represent a linear or branched, saturated hydrocarbon chain having the indicated number of carbon atoms. Exam- ples of such groups include, but are not limited to methyi, ethyl, n-propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl, pentyl, isopentyl, hexyl, isohexyl and the like.
The term "Ca.e-cycloalkyl” as used herein, alone or in combination, represent a satu- rated monocyclic hydrocarbon group having the indicated number of carbon atoms. Examples of such groups include, but are not limited to cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl and the like.
The term "C,.c-alkenyl" as used herein, represent an olefinically unsaturated branched or straight hydrocarbon group having from 2 to the specified number of carbon at- oms and at least one double bond. Examples of such groups include, but are not limited to, vinyl, 1-propenyl, 2-propenyl, allyl, iso-propenyl, 1,3-butadienyl, 1-butenyl, hexenyl, pentenyl and the like.
The term "C,.e-alkyny!" as used herein, represent an unsaturated branched or straight hydrocarbon group having from 2 to the specified number of carbon atoms and at least one triple bond. Examples of such groups include, but are not limited to, 1-propynyl, 2- propynyl, 1-butynyl, 2-butynyl, 1-pentynyl, 2-pentynyl and the like.
The term "Cq¢-alkenynyl" as used herein, represent an unsaturated branched or straight hydrocarbon group having from 4 to the specified number of carbon atoms and both at least one double bond and at least one triple bond. Examples of such groups include, but are not limited to, 1-penten-4-ynyl, 3-penten-1-ynyl, 1,3-hexadiene-5-ynyl and the like. ’ The term “C,s-alkoxy” as used herein, alone or in combination, refers to a straight or branched configuration linked through an ether oxygen having its free valence bond from the ether oxygen. Examples of linear alkoxy groups are methoxy, ethoxy, propoxy, butoxy, pentoxy, hexoxy and the like. Examples of branched alkoxy are isopropoxy, sec-butoxy, tert-butoxy, isopentyloxy, isohexyloxy and the like.
The term “Ca s-cycloalkoxy” as used herein, alone or in combination, represent a saturated monocyclic hydrocarbon group having the indicated number of carbon atoms linked through an ether oxygen having its free valence bond from the ether oxygen. Examples of cycloalkoxy groups are cyclopropyloxy, cyclobutyloxy, cyclopentyloxy, cyclohexyloxy and the like.
The term "Cs-alkylthio" as used herein, alone or in combination, refers to a straight or branched monovalent substituent comprising a C1.s-alkyl group linked through a divalent sulfur atom having its free valence bond from the sulfur atom and having 1 to 6 carbon atoms e.g. methylthio, ethylthio, propylthio, butylthio, pentyithio and the like.
The term “Cy e-cycloalkylthio” as used herein, alone or in combination, represent a saturated monocyclic hydrocarbon group having the indicated number of carbon atoms linked through a divalent sulfur atom having its free valence bond from the sulfur atom. Examples of cycloalkoxy groups are cyclopropyithio, cyclobutylthio, cyclopentylthio, cyclohexyithio and the like.
The term “C,-alkylamino” as used herein, alone or in combination, refers to a straight or branched monovalent substituent comprising a C1.s-alkyl group linked through 5 amino having a free valence bond from the nitrogen atom e.g. methylamino, ethylamino, propylamino, butylamino, pentylamino and the like.
The term “C,.g-cycloalkylamino” as used herein, alone or in combination, represent a saturated monocyclic hydrocarbon group having the indicated number of carbon atoms linked through amino having a free valence bond from the nitrogen atom e.g. cyclopropylamino, cyclobutylamino, cyclopentylamino, cyclohexylamino and the like.
The term “C,¢-alkoxyCq.¢-alkyl” as used herein, alone or in combination, refers to Cs. e-alkyl as defined herein whereto is attached a Cy¢-alkoxy as defined herein, e.g. methoxymethyl, ethoxymethyl, methoxyethyl, ethoxyethyl and the like.
The term "ary!" as used herein refers to an aromatic monocyclic or an aromatic fused bi- or tricyclic hydrocarbon group e.g. phenyl, naphthyl, anthracenyl, phenanthrenyl, azulenyl and the like.
The term "arylene” as used herein refers to divalent aromatic monocyclic or a divalent aromatic fused bi- or tricyclic hydrocarbon group e.g. phenylene, naphthylene and the like.
The term "halogen" means fluorine, chlorine, bromine or iodine.
The term "perhalomethyl" means trifluoromethyl, trichloromethyl, tribromomethyl or triiocdomethyi.
The term "perhalomethoxy” means trifluoromethoxy, trichloromethoxy, tribromo- methoxy or triiodomethoxy.
The term "C,.-dialkylamino" as used herein refers to an amino group wherein the two hydrogen atoms independently are substituted with a straight or branched, saturated hydrocarbon chain having the indicated number of carbon atoms; such as dimethylamino, N- ethyl-N-methylamino, diethylamino, dipropylamino, N-(n-butyl)-N-methylamino, di(n- pentyl)amino and the like. - ~The term "acyl" as used herein refers to a monovalent substituent comprising a Cys - alkyl group linked through a carbonyl group; such as e.g. acetyl, propionyl, butyryl, isobutyryl, pivaloy!, valeryl and the like.
The term "heteroaryl" as used herein, alone or in combination, refers to a monovalent substituent comprising a 5-7 membered monocyclic aromatic system or a 8-10 membered bicyclic aromatic system containing one or more heteroatoms selected from nitrogen, oxygen and sulfur, e.g. furyl, thienyl, pyrrolyl, imidazolyl, pyrazolyl, triazolyl,
pyrazinyl, pyrimidinyl, pyridazinyl, isothiazolyl, isoxazolyl, oxazolyl, oxadiazolyl, thiadiazolyl, quinolyl, isoquinolyl, quinazolinyl, quinoxalinnyl, indolyl, benzimidazolyl, benzofuranyi, pteridinyl and purinyl and the like.
The term “heteroaryloxy" as used herein, alone or in combination, refers to a heteroaryl as defined herein linked to an oxygen atom having its free valence bond from the oxygen atom e.g. pyrrolyloxy, imidazolyloxy, pyrazolyloxy, triazolyloxy, pyrazinyloxy, pyrimidinyloxy, pyridazinyloxy, isothiazolyloxy, isoxazolyloxy, oxazolyloxy, oxadiazolyloxy, thiadiazolyloxy, quinolinyloxy, isoquinolinyloxy, quinazolinyloxy, quinoxalinyloxy, indoltioxy, benzimidazolyloxy, benzofuranyloxy, pteridinyloxy and purinyloxy and the like.
The term "aralkyl" as used herein refers to a straight or branched saturated carbon chain containing from 1 to 6 carbons substituted with an aromatic carbohydride; such as benzyl, phenethyl, 3-phenylpropyl, 1-naphthyimethyl, 2-(1-naphthyl)ethyl and the like.
The term "aryloxy" as used herein refers to phenoxy, 1-naphthyloxy, 2-naphthyloxy and the like.
The term "aralkoxy" as used herein refers to a Cy.-alkoxy group substituted with an aromatic carbohydride, such as benzyloxy, phenethoxy, 3-phenylpropoxy, 1- naphthylmethoxy, 2-(1-naphtyl)ethoxy and the like. - The term "heteroaralkyl" as used herein refers to a straight or branched saturated carbon chain containing from 1 to 6 carbons substituted with a heteroaryl group; such as (2- furyhmethyl, (3-furyl)methyl, (2-thienyl)methyl, (3-thienyl)methyl, (2-pyridyljmethyl, 1-methyl- 1-(2-pyrimidyl)ethyl and the like.
The term "heteroaralkoxy" as used herein refers to a heteroarylalkyl as defined herein linked to an oxygen atom having its free valence bond from the oxygen atom, e.g. (2- furyl)methyl, (3-furyl)methyl, (2-thienyl)methyl, (3-thienyl)methyl, (2-pyridy)methyl, 1-methyl- 1-(2-pyrimidyl)ethy! linked to oxygen, and the like.
The term "arylthio" as used herein, alone or in combination, refers to an aryl group linked through a divalent sulfur atom having its free valence bond from the sulfur atom, the aryl group optionally being mono- or polysubstituted with Cys-alkyl, halogen, hydroxy or Cy.s-alkoxy; e.g. phenylthio, (4-methylphenyl)- thio, (2-chlorophenyljthio and the like.
Certain of the above defined terms may occur more than once in the structural formulae, and upon such occurrence each term shall be defined independently of the other.
The term “optionally substituted” as used herein means that the groups in question are either unsubstituted or substituted with one or more of the substituents specified. When the groups in question are substituted with more than one substituent the substituents may be the same or different.
DESCRIPTION OF THE INVENTION
The present invention relates to compounds of the general formula (1):
X Y xX
I
} YAN Ar (0)
Ne rR, wherein X is aryl, fluorenyl or heteroaryl each of which is optionally substituted with one or more substituents selected from halogen, hydroxy, cyano, amino, Cs-alkylamino, Cy.e-dialkylamino, Cas-cycloalkyl- amino or carboxy; or e Cgalkyl, Cye-cycloalkyl, Cag-alkenyl, Cog-alkynyl, Cis-alkoxy, Cas-Cycloalkoxy,
Cie-alkylthio or Cae-cycloalkylthio each of which is optionally substituted with halo- gen; or « aryl, aryloxy, aryithio, acyl, aralkyl, aralkoxy, heteroaryl, heteroaralkyl, heteroaryloxy, heteroaralkoxy each of which is optionally substituted with halogen, perhalomethyl, perhalomethoxy or Cqs-alkyl; and
Y is aryl or heteroaryl each of which is optionally substituted with one or more substituents selected from halogen, hydroxy, cyano, amino, Cy-alkylamino, C,.s-dialkylamino, Cas-cycloakkyl amino, carboxy ; or e Cyg-alkyl, Cae-cycloalkyl, C,s-alkenyl, C,e-alkynyl, Cig-alkoxy, Cae-cycloalkoxy,
Cys-alkylthio or Cae-cycloalkylthio each of which is optionally substituted with halo- : gen; or « aryl, aryloxy, arylthio, acyl, aralkyl, aralkoxy, heteroaryl, heteroaralkyl, heteroaryloxy, heteroaralkoxy each of which is optionally substituted with halogen, perhalomethyl or perhalomethoxy; or :
Y is Cqe-alkyl, Cag-cycloalkyl, Czs-alkenyl, C..e-alkynyl, Cse-alkenynyl; and
Ar is arylene which is optionally substituted with one or more halogen; and
ZisOorS; and
Q is «(CH,),— whereinnis 0, 1, 2 or 3; and
R; is hydrogen or halogen; or
R; is Cy-alkyl, Cag-cycloalkyl, Ci.e-alkoxy, Cs.e-cycloalkoxy each of which is optionally sub- stituted with one or more substituents selected from halogen, hydroxy, carboxy, amino or cyano; and
R; is hydrogen, C,.-alkyl, Css-cycloalkyl, Co.¢-alkenyl, C,s-alkynyl, C4s-alkenynyl or aryl; provided that X and Y independently is not a pyridine ring; or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable solvate thereof, ' or any tautomeric forms, stereoisomers, mixture of stereoisomers including a racemic mix- ture, or polymorphs.
In one embodiment, the present invention is concerned with compounds of formula (1) wherein X is aryl, fluorenyl or heteroaryl each of which is optionally substituted with one or more substituents selected from « halogen; or « Cis-alkyl, Cis-alkoxy, or Cqs-alkyithio each of which is optionally substituted with halogen; or « aryl, aryloxy, arylthio, aralkyl, aralkoxy, heteroaryl, heteroaralkyl, heteroaryloxy or het- eroaralkoxy each of which is optionally substituted with halogen, perhalomethyl, perha- lomethoxy or Cy.g-alkyl. -
In another embodiment, the present invention is concerned with compounds of formula (I) wherein X is aryl, fluorenyl or heteroaryl each of which is optionally substituted with one or more substituents selected from o halogen; or « aryl, aryloxy or heteroaryl each of which is optionally substituted with halogen, perha- lomethyl, perhalomethoxy or Cy.s-alkyl.
in another embodiment, the present invention is concerned with compounds of for- mula (I) wherein X is aryl, which is optionally substituted with one or more substituents se- lected from * halogen; or «aryl, aryloxy or heteroaryl each of which is optionally substituted with halogen, perha- lomethyl, perhalomethoxy or Ci.s-alkyl.
In another embodiment, the present invention is concerned with compounds of for- mula (1) wherein X is phenyl, which is optionally substituted with one or more substituents selected from eo bromine; or s phenyl or phenyloxy.
In another embodiment, the present invention is concerned with compounds of formula (I) wherein X is heteroaryl, which is optionally substituted with one or more substituents se- lected from « halogen; or ¢ aryl or heteroaryl each of which is optionally substituted with halogen, perhalomethyl, per- halomethoxy or Cqs-alkyl.
In another embodiment, the present invention is concerned with compounds of for- mula (1) wherein X is heteroaryl, which is optionally substituted with aryl.
In another embodiment, the present invention is concerned with compounds of for- mula (1) wherein X is thiazolyl, which is optionally substituted with phenyl.
In another embodiment, the present invention is concemed with compounds of for- mula (1) wherein X is fluorenyl. in another embodiment, the present invention is concemed with compounds of for- mula ({) wherein Y is aryl or heteroaryl each of which is optionally substituted with one or more substituents selected from ¢ halogen; or e C,s-alkyl, C4.¢-alkoxy or Cq¢-alkylthio each of which is optionally substituted with halogen; or ee aryl, aryloxy, arylthio, aralkyl, aralkoxy, heteroaryl, heteroaralkyl, heteroaryloxy or het- eroaralkoxy each of which is optionally substituted with halogen, perhalomethyl, perha- lomethoxy or Cqg-alkyl.
In another embodiment, the present invention is concemed with compounds of for- mula (1) wherein Y is aryl or heteroaryl each of which is optionally substituted with one or more substituents selected from
+ halogen; or *» Cygalkyl, or « aryl or heteroaryl each of which is optionally substituted with halogen, perhalomethyl, per- halomethoxy or Cy.¢-alkyl. in another embodiment, the present invention is concemed with compounds of for- mula (I) wherein Y is aryl, which is optionally substituted with one or more halogens.
In another embodiment, the present invention is concerned with compounds of for- mula (I) wherein Y is phenyl, which is optionally substituted with one or more halogens. "In another embodiment, the present invention is concerned with compounds of for- mula (I) wherein Y is heteroaryl, which is optionally substituted with one or more halogens.
In another embodiment, the present invention is concerned with compounds of for- mula (1) wherein Y is C,g-alkyl.
In another embodiment, the present invention is concerned with compounds of formula (I) wherein Y is methyl.
In another embodiment, the present invention is concerned with compounds of for- mula (I) wherein Ar is arylene, which is optionally substituted with one or more halogens.
In another embodiment, the present invention is concemed with compounds of formula (lI) wherein Ar is phenylene, which is optionally substituted with one or more halogens.
In another embodiment, the present invention is concerned with compounds of formula (I) wherein Z is O. : In another embodiment, the present invention is concerned with compounds of for- mula (I) whereinnis 1 or 2.
In another embodiment, the present invention is concerned with compounds of formula (I) wherein R, is hydrogen.
In another embodiment, the present invention is concerned with compounds of formula (I) wherein R; is Cis-alkyl.
In another embodiment, the present invention is concerned with compounds of formula (1) wherein Ry is Cy.5-alkoxy.
In another embodiment, the present invention is concerned with compounds of formula (I) wherein wherein R; is hydrogen or Cq¢-alkyl.
In another embodiment, the present invention is concerned with compounds of for- mula (I) wherein R, is hydrogen, methyl or ethyl.
In another embodiment, the present invention is concerned with compounds of formula | wherein alkyl is methyl or ethyl.
In another embodiment, the present invention is concerned with compounds of formula | wherein alkenyl is vinyl or 1-propenyl. : in another embodiment, the present invention is concerned with compounds of formula | wherein alkynyl is 1-propynyl.
In another embodiment, the present invention is concerned with compounds of formula | wherein alkenynyl is 1-pentene-4-yne.
In another embodiment, the present invention is concerned with compounds of formula | wherein alkoxy is methoxy, ethoxy, isopropoxy or cyclopropoxy.
In another embodiment, the present invention is concerned with compounds of formula | wherein aryl is phenyl.
In another embodiment, the present invention is concerned with compounds of formula | wherein arylene is phenylene.
In another embodiment, the present invention is concerned with compounds of formula | wherein halogen is fluorine, bromine or chlorine.
In another embodiment, the present invention is concerned with compounds of formula | wherein perhalomethyl is trifluoromethyl. in another embodiment, the present invention is concerned with compounds of ’ formula | wherein heteroaryl is, thiazolyl.
In another embodiment, the present invention is concerned with compounds of formula [ wherein aralkyl is benzyl. in another embodiment, the present invention is concerned with compounds of formula | wherein aryloxy is phenoxy.
In another embodiment, the present invention is concerned with compounds of formula | wherein aralkoxy is benzyloxy.
In another embodiment, the present invention is concerned with compounds of formula | wherein the substituents R, and Y are arranged in a trans-configuration.
In another embodiment, the present invention is concerned with compounds of formula | wherein the substituents R; and Y are arranged in a cis-configuration. "In another embodiment, the present invention is concerned with compounds of formula | which is a PPARS agonist.
In another embodiment, the present invention is concerned with compounds of formula | which selective PPARS agonist.
Examples of specific compounds of the invention are: 3-{3-[3,3-Bis-(4-bromo-phenyl)-allyloxy]-phenyl}-propionic acid ethyl ester, 3-{3-[3,3-Bis-(4-bromo-phenyl)-allyloxy}-phenyi}-propionic acid,
3-{3-[3,3-Bis-(4-bromo-phenyl)-allyloxy}-phenyl}-acetic acid ethyl ester, 3-{3-[3,3-Bis-(4-bromo-phenyl)-allyloxy}-phenyl}-acetic acid, 3-{4-3,3-Bis-(4-bromo-phenyl)-allyloxyl-phenyl}-propionic acid ethyl ester, 3-{4-[3,3-Bis-(4-bromo-phenyl)-allyloxy}-phenyl}-propionic acid, {4-3,3-Bis-(4-bromo-phenyl)-allyloxy]-phenyl}-acetic acid methyl ester, {4-[3,3-Bis-(4-bromo-phenyl)-allyloxyl-phenyl}-acetic acid, {4-13,3-Bis-(4-bromo-phenyl)-allyloxy}-3-chloro-phenyli}-acetic acid ethyl ester, {4-[3,3-Bis-(4-bromo-phenyl)-allyloxy}-3-chloro-phenyl}-acetic acid, (E)-{4-[3-(4-Bromo-phenyl)-3-phenyl-allyloxyl-phenyl}-acetic acid methyl ester, (E)44-[3-(4-Bromo-phenyl)-3-phenyl-allyloxy]-phenyl}-acetic acid, (2)-{4-[3-(4-Bromo-phenyl)-3-phenyl-allyloxy]-phenyi}-acetic acid methyl ester, (E)44-[3-(4-Bromo-phenyl)-3-phenyl-allyloxy}-3-chloro-phenyi}-acetic acid ethyl ester, (E)4{4-[3~(4-Bromo-phenyl)-3-phenyl-allyloxy]-3-chloro-phenyl}-acetic acid, or a salt thereof with a pharmaceutically acceptable acid or base, or any optical isomer or mix- ture of optical isomers, including a racemic mixture, or any tautomeric forms.
Other examples of specific compounds of the invention are: (E){4-3-(8H-Fluoren-2-yl)-but-2-enyloxy]-phenyl}-acetic acid methyl ester, : (E)-{4-[3-(9H-Fluoren-2-yf)-but-2-enyloxy]-phenyl}-acetic acid, (E)-{4-[3-(9H-Fluoren-2-yi)-but-2-enyloxy]-phenyl}-propionic acid ethyl ester, (E){4-[3-(9H-Fluoren-2-yl)-but-2-enyloxy]-phenyl}-propionic acid, or a salt thereof with a pharmaceutically acceptable acid or base, or any optical isomer or mix- ture of optical isomers, including a racemic mixture, or any tautomeric forms.
Other examples of specific compounds of the invention are: (E)-{4-[3-(4-Phenoxy-phenyl)-but-2-enyloxy]-phenyl}-acetic acid methyl ester, (E){4-[3-(4-Phenoxy-phenyl)-but-2-enyloxy]-phenyl}-acetic acid, (E)-{3-[3-(4'-Bromo-biphenyl-4-yl)-but-2-enyloxy]-phenyl}-acetic acid ethyl ester, (E)4{3-{3-(4'-Bromo-biphenyl-4-yl)-but-2-enyloxy]-phenyl}-acetic acid, (E)H{4-[3-(4"-Bromo-biphenyl-4-yl)-but-2-enyloxy}-phenyl}-acetic acid methyl ester, (E){4-[3-(4'-Bromo-biphenyl-4-yl)-but-2-enyloxy]-phenyli}-acetic acid, (E){3-Chloro-4-[3-(4-fluoro-phenyl)-3-(2-phenyl-thiazol-5-yl)-allyloxy]-phenyl}-acetic acid ethyl ester, (E){3-Chloro-4-[3-(4-fluoro-phenyl)-3-(2-phenyl-thiazol-5-yl)-allyloxy]-phenyl}-acetic acid, (2)4{3-Chloro-4-{3-(4-fluoro-phenyl)-3-(2-phenyl-thiazol-5-yl)-allyloxy]-phenyl}-acetic acid ethyl ester, (E)-{3-Chloro-4-[3-(4-fluoro-phenyl)-3-(2-phenyl-thiazol-5-yl)-allyloxy]-phenyl}-acetic acid,
(E)-{3-Chloro-4-[3-(2-phenyl-thiazol-5-yl)-but-2-enyloxy]-phenyl}-acetic acid ethyl ester, (E)-{3-Chloro-4-[3-(2-phenyl-thiazol-5-yl)-but-2-enyloxyl-phenyl}-acetic acid, (2)-{3-Chloro-4-{3-(2-phenyl-thiazol-5-y!)-but-2-enyloxy]-phenyl}-acetic acid ethyl ester, (2)-{3-Chloro-4-{3~(2-phenyl-thiazol-5-yl)-but-2-enyloxyl-phenyl}-acetic acid, (E)-{4-{3-Biphenyl-4-yl-3-(2-phenyl-thiazol-5-yl)-allyloxy]-3-chloro-phenyl}-acetic acid ethy! ester, (E)<{4-[3-Biphenyl-4-yl-3-(2-phenyl-thiazol-5-yl)-allyloxy]-3-chloro-phenyl}-acetic acid, (2){4-[3-Biphenyi-4-yl-3-(2-phenyl-thiazol-5-yl)-allyloxy]-3-chloro-phenyl}-acetic acid ethyl aster, (Z){4-{3-Biphenyl-4-yl-3-(2-phenyl-thiazol-5-yl)-allyloxy]-3-chloro-phenyl}-acetic acid, or a salt thereof with a pharmaceutically acceptable acid or base, or any optical isomer or mix- ture of optical isomers, including a racemic mixture, or any tautomeric forms.
Other examples of compounds of the invention are: {4-[3,3-Bis-(4-fluoro-phenyl)-allyloxy}-phenyl}-acetic acid, {4-[3,3-Bis-(4-chloro-phenyl)-allyloxy]-phenyl}-acetic acid, {4-[3,3-Bis-(4-iodo-phenyl)-allyloxyl-phenyi}-acetic acid, {4-[3,3-Bis-(4-trifluoromethyl-phenyl)-allyloxy]-phenyi}-acetic acid, : {4-[3,3-Bis-(4-cyano-phenyl)-allyloxy]-phenyi}-acetic acid, {4-[3,3-Bis-biphenyl)-4-yl-allyloxy]-phenyl}-acetic acid, {4-3,3-Bis-(4-furan-2-yl-phenyl)-allyloxy]-phenyl}-acetic acid, {4-[3,3-Bis-(4-furan-3-yl-phenyl)-allyloxy]-phenyl}-acetic acid, {4-(3,3-Bis-(4-thiophen-2-yl-phenyl)-allyloxy}-phenyl}-acetic acid, {4-[3,3-Bis-(4-thiophen-3-yl-phenyl)-allyloxy}-phenyl}-acetic acid, {4-{3,3-Bis-(4-fluoro-phenyl)-allyloxy]-3-chloro-phenyl}-acetic acid, {4-[3,3-Bis-(4-chloro-phenyl}-allyloxy]-3-chloro-phenyl}-acetic acid, {4-[3,3-Bis-(4-iodo-phenyl)-allyloxy}-3-chloro-phenyl}-acetic acid, {4-[3,3-Bis-(4-trifluoromethyl-phenyl)-3-chloro-allyloxy]-phenyl}-acetic acid, {4-(3,3-Bis-(4-cyano-phenyl)-allyloxy]-3-chloro-phenyl}-acetic acid, {4-[3,3-Bis-biphenyl)-4-yl-allyloxy]-3-chloro-phenyl}-acetic acid, {4-[3,3-Bis-(4-furan-2-yl-phenyl)-allyloxy]-3-chioro-phenyl}-acetic acid, {4-[3,3-Bis-(4-furan-3-yl-phenyl)-allyloxy]-3-chloro-phenyl}-acetic acid, {4-[3,3-Bis-(4-thiophen-2-yl-phenyl)-allyloxy]-3-chloro-phenyli}-acetic acid, {4-[3,3-Bis-(4-thiophen-3-yl-phenyl)-allyloxy]-3-chloro-phenyl}-acetic acid, {4-[3,3-Bis-(4-fluoro-phenyl)-allyloxy}-3-bromo-phenyl}-acetic acid, {4-[3,3-Bis-(4-chloro-phenyl)-allyloxy]-3-bromo-phenyl}-acetic acid,
{4-[3,3-Bis-(4-iodo-phenyi)-allyloxy]-3-bromo-phenyl}-acetic acid, {4-[3,3-Bis-(4-trifluoromethyl-phenyl)-3-bromo-allyloxyl-phenyl}-acetic acid, {4-[3,3-Bis-(4-cyano-phenyl)-allyloxy]-3-bromo-phenyl}-acetic acid, {4-[3,3-Bis-biphenyl)-4-yl-allyloxy]-3-bromo-phenyli}-acetic acid,
{4-3,3-Bis-(4-furan-2-yl-phenyl)-allyloxy]-3-bromo-phenyl}-acetic acid, {4-[3,3-Bis-(4-furan-3-yl-phenyl)-allyloxy}-3-bromo-phenyl}-acetic acid, {4-[3,3-Bis-(4-thiophen-2-yl-phenyl)-allyloxy]-3-bromo-phenyl}-acetic acid, {4-[3,3-Bis-(4-thiophen-3-yl-phenyl)-allyloxy]-3-bromo-phenyl}-acetic acid, {4-[3,3-Bis-(4-fluoro-phenyl)-allyloxy}-3-iodo-phenyl}-acetic acid,
{4-[3,3-Bis-(4-chloro-phenyl)-allyloxy}-3-iodo-phenyl}-acetic acid, _
{4-[3,3-Bis-(4-iodo-phenyl)-allyloxy}-3-iodo-phenyl}-acetic acid, 0 {4-[3,3-Bis-(4-trifluoromethyl-phenyl)-3-iodo-allyloxy}-phenyl}-acetic acid, : {4-[3,3-Bis-(4-cyano-phenyl)-allyloxy}-3-iodo-phenyl}-acetic acid, {4-[3,3-Bis-biphenyl)-4-yl-allyloxy}-3-iodo-phenyl}-acetic acid,
{4-[3,3-Bis-(4-furan-2-yl-phenyl)-allyloxy]-3-iodo-phenyl}-acetic acid, {4-[3,3-Bis-(4-furan-3-yl-phenyl)-allyloxy}-3-iodo-phenyl}-acetic acid, {4-[3,3-Bis-(4-thiophen-2-yl-phenyl)-allyloxy}-3-iodo-phenyl}-acetic acid,
’ {4-[3,3-Bis-(4-thiophen-3-yl-phenyl)-allyloxy]-3-iodo-phenyl}-acetic acid, 3-{4-[3,3-Bis-(4-fluoro-phenyl)-allyloxy]-phenyl}-propionic acid,
3-{4-[3,3-Bis-(4-chloro-phenyl)-allyloxy]-phenyl}-propionic acid, 3-{4-[3,3-Bis-(4-iodo-phenyl)-allyloxy]-phenyl}-propionic acid, 3-{4-[3,3-Bis-(4-trifluoromethyl-phenyl)-allyloxy]-phenyl}-propionic acid, 3-{4-[3,3-Bis-(4-cyano-phenyi)-allyloxy]-phenyl}-propionic acid, 3-{4-[3,3-Bis-biphenyl)-4-yl-allyloxy]-phenyl}-propionic acid,
3-{4-[3,3-Bis-(4-furan-2-yl-phenyl)-allyloxy]-phenyl}-propionic acid, 3-{4-[3,3-Bis-(4-furan-3-yl-phenyl)-allyloxy}-phenyl}-propionic acid, 3-{4-[3,3-Bis-(4-thiophen-2-yl-phenyl)-allyloxyl-phenyl}-propionic acid, : 3-{4-[3,3-Bis-(4-thiophen-3-yl-phenyl)-allyloxy]-phenyl}-propionic acid,. 3-{4-[3,3-Bis-~(4-fluoro-phenyl)-allyloxy}-3-chloro-phenyl}-propionic acid,
3-{4-[3,3-Bis-(4-chloro-phenyi)-allyloxy]-3-chloro-phenyl}-propionic acid, 3-{4-[3,3-Bis-(4-iodo-phenyl)-allyloxy]}-3-chloro-phenyl}-propionic acid, 3-{4-[3,3-Bis-(4-trifluoromethyl-phenyl)-3-chloro-allyloxy]-phenyl}-propionic acid, 3-{4-[3,3-Bis-(4-cyano-phenyi)-allyloxy]-3-chloro-phenyi}-propionic acid, 3-{4-[3,3-Bis-biphenyl)-4-yl-allyloxy]-3-chloro-phenyl}-propionic acid,
3-{4-[3,3-Bis-(4-furan-2-yl-phenyl)-allyloxy]-3-chloro-phenyl}-propionic acid,
3-{4-[3,3-Bis-(4-furan-3-yl-phenyl)-allyloxy]-3-chloro-phenyl}-propionic acid, 3-{4-{3,3-Bis-(4-thiophen-2-yl-phenyl)-allyloxy]-3-chloro-phenyl}-propionic acid, 3-{4-[3,3-Bis-(4-thiophen-3-yl-phenyl)-allyloxy]-3-chioro-phenyl}-propionic acid, 3-{4-3,3-Bis-(4-fluoro-phenyl)-allyloxy]-3-bromo-phenyl}-propionic acid, 3-{4-{3,3-Bis-(4-chloro-phenyl)-allyloxy}-3-bromo-phenyl}-propionic acid, 3-{4-[3,3-Bis-(4-iodo-phenyl)-allyloxy]-3-bromo-phenyl}-propionic acid, 3-{4-[3,3-Bis-(4-trifluoromethyl-phenyl)-3-bromo-ailyloxy}-phenyl}-propionic acid, 3-{4-[3,3-Bis-(4-cyano-phenyl)-allyloxy]-3-bromo-phenyl}-propionic acid, 3-{4-[3,3-Bis-biphenyl)-4-yl-allyloxy]-3-bromo-phenyi}-propionic acid, 3-{4-[3,3-Bis-(4-furan-2-yl-phenyl)-allyloxy]-3-bromo-phenyl}-propionie acid, 3-{4-[3,3-Bis-(4-furan-3-yl-phenyl)-allyloxy]-3-bromo-phenyl}-propionic acid, 3-{4-[3,3-Bis-(4-thiophen-2-yl-phenyl)-allyloxy]-3-bromo-phenyl}-propionic acid, 3-{4-[3,3-Bis-(4-thiophen-3-yl-phenyl)-allyloxy]-3-bromo-phenyl}-propionic acid, 3-{4-[3,3-Bis-(4-fluoro-phenyl)-allyloxy]-3-iodo-phenyi}-propionic acid, 3-{4-[3,3-Bis-(4-chloro-phenyl)-allyloxy}-3-iodo-phenyl}-propionic acid, 3-{4-[3,3-Bis-(4-iodo-phenyi)-allyloxy]-3-iodo-phenyl}-propionic acid, 3-{4-[3,3-Bis-(4-trifluoromethyl-phenyl)-3-iado-allyloxy}-phenyl}-propionic acid, : 3-{4-[3,3-Bis-(4-cyano-phenyl)-allyloxy]-3-iodo-phenyl}-propionic acid, 3-{4-[3,3-Bis-biphenyl)-4-yl-allyloxy]-3-iodo-phenyl}-propionic acid, 3-{4-[3,3-Bis-(4-furan-2-yl-phenyl)-allyloxy}-3-iodo-phenyl}-propionic acid, 3-{4-[3,3-Bis-(4-furan-3-yl-phenyl)-allyloxy]-3-iodo-phenyl}-propionic acid, 3-{4-[3,3-Bis-(4-thiophen-2-yl-phenyl)-allyloxy]-3-iodo-phenyl}-propionic acid, 3-{4-[3,3-Bis-(4-thiophen-3-yl-phenyl)-allyloxy]-3-iodo-phenyl}-propionic acid, or a salt thereof with a pharmaceutically acceptable acid or base, or any optical isomer or mix- ture of optical isomers, including a racemic mixture, or any tautomeric forms.
The present invention also encompasses pharmaceutically acceptable salts of the present compounds. Such salts include pharmaceutically acceptable acid addition salts, + pharmaceutically acceptable base addition salts, pharmaceutically acceptable metal salts, ammonium and alkylated ammonium salts. Acid addition salts include salts of inorganic acids as well as organic acids. Representative examples of suitable inorganic acids include hydro- chloric, hydrobromic, hydreiodic, phosphoric, sulfuric, nitric acids and the like. Representative examples of suitable organic acids include formic, acetic, trichloroacetic, trifluoroacetic, propionic, benzoic, cinnamic, citric, fumaric, glycolic, lactic, maleic, malic, malonic, mandelic, oxalic, picric, pyruvic, salicylic, succinic, methanesulfonic, ethanesulfonic, tartaric, ascorbic, pamoic, bismethylene salicylic, ethanedisulfonic, gluconic, citraconic, aspartic, stearic,
palmitic, EDTA, glycolic, p-aminobenzoic, glutamic, benzenesulfonic, p-toluenesulfonic acids, sulphates, nitrates, phosphates, perchlorates, borates, acetates, benzoates, hydroxynaph- thoates, glycerophosphates, ketoglutarates and the like. Further examples of pharmaceuti- cally acceptable inorganic or organic acid addition salts include the pharmaceutically accept- able salts listed in J. Pharm. Sci. 1977, 66, 2, which is incorporated herein by reference. Ex- amples of metal salts include lithium, sodium, potassium, magnesium, zinc, calcium salts and the like. Examples of amines and organic amines include ammonium, methylamine, di- methylamine, trimethylamine, ethylamine, diethylamine, propylamine, butylamine, tetrame- thylamine, ethanolamine, diethanolamine, triethanolamine, meglumine, ethylenediamine, choline, N,N'-dibenzylethylenediamine, N-benzyiphenylethylamine, N-methyl-D-glucamine, guanidine and the like. Examples of cationic amino acids include lysine, arginine, histidine and the like.
The pharmaceutically acceptable salts are prepared by reacting the compound of formula | with 1 to 4 equivalents of a base such as sodium hydroxide, sodium methoxide, so- dium hydride, potassium t-butoxide, calcium hydroxide, magnesium hydroxide and the like, in solvents like ether, THF, methanol, t-butanol, dioxane, isopropanol, ethanal etc. Mixture of solvents may be used. Organic bases like lysine, arginine, diethanolamine, choline, guandine ’ and their derivatives etc. may also be used. Alternatively, acid addition salts wherever appli- cable are prepared by treatment with acids such as hydrochloric acid, hydrobromic acid, ni- tric acid, sulfuric acid, phosphoric acid, p-toluenesulphonic acid, methanesulfonic acid, acetic acid, citric acid, maleic acid salicylic acid, hydroxynaphthoic acid, ascorbic acid, palmitic acid, succinic acid, benzoic acid, benzenesulfonic acid, tartaric acid and the like in solvents like ethyl acetate, ether, alcohols, acetone, THF, dioxane etc. Mixture of solvents may also be used.
The stereoisomers of the compounds forming part of this invention may be prepared by using reactants in their single enantiomeric form in the process wherever possible or by conducting the reaction in the presence of reagents or catalysts in their single enantiomer form or by resolving the mixture of stereoisomers by conventional methods. Some of the preferred methods include use of microbial resolution, enzymatic resolution, resolving the diastereomeric salts formed with chiral acids such as mandelic acid, camphorsuifonic acid, : tartaric acid, lactic acid, and the like wherever applicable or chiral bases such as brucine, (R)- or (S)-phenylethylamine, cinchona alkaloids and their derivatives and the like. Com- monly used methods are compiled by Jaques et al in "Enantiomers, Racemates and Resolu- tion" (Wiley Interscience, 1981). More specifically the compound of formula | may be con- verted to a 1:1 mixture of diastereomeric amides by treating with chiral amines, aminoacids,
aminoalcohols derived from aminoacids; conventional reaction conditions may be employed to convert acid into an amide; the dia-stereomers may be separated either by fractional crys- tallization or chromatography and the stereoisomers of compound of formula | may be pre- pared by hydrolysing the pure diastereomeric amide.
Various polymorphs of compound of general formula | forming part of this invention may be prepared by crystallization of compound of formula | under different conditions. For example, using different solvents commonly used or their mixtures for recrystallization; crys- tallizations at different temperatures; various modes of cooling, ranging from very fast to very slow cooling during crystallizations. Polymorphs may also be obtained by heating or melting the compound followed by gradual or fast cooling. The presence of polymorphs may be de- termined by solid probe nmr spectroscopy, ir spectroscopy, differential scanning calorimetry, powder X-ray diffraction or such other techniques.
The invention also encompasses prodrugs of the present compounds, which on ad- ministration undergo chemical conversion by metabolic processes before becoming active pharmacological substances. In general, such prodrugs will be functional derivatives of the present compounds, which are readily convertible in vivo into the required compound of the formula (1). Conventional procedures for the selection and preparation of suitable prodrug ) derivatives are described, for example, in “Design of Prodrugs”, ed. H. Bundgaard, Elsevier, 1985.
The invention also encompasses active metabolites of the present compounds.
The invention also relates to pharmaceutical compositions comprising, as an active ingredient, at least one compound of the formula | or any optical or geometric isomer or tautomeric form thereof including mixtures of these or a pharmaceutically acceptable salt thereof together with one or more pharmaceutically acceptable carriers or diluents.
Furthermore, the invention relates to the use of compounds of the general formula or their tautomeric forms, their stereoisomers, their polymorphs, their pharmaceutically ac- ceptable salts or pharmaceutically acceptable solvates thereof for the preparation of a phar- maceutical composition for the treatment and/or prevention of conditions mediated by nu- clear receptors, in particular the Peroxisome Proliferator-Activated Receptors (PPAR) such as the conditions mentioned above.
In another aspect, the present invention relates to a method of treating and/or preventing Type | or Type Ii diabetes.
In a still further aspect, the present invention relates to the use of one or more compounds of the general formula | or pharmaceutically acceptable salts thereof for the preparation of a pharmaceutical composition for the treatment and/or prevention of Type | or
Type I! diabetes. :
In a still further aspect, the present compounds are useful for the treatment and/or prevention of IGT.
In a still further aspect, the present compounds are useful for the treatment and/or prevention of Type 2 diabetes.
In a still further aspect, the present compounds are useful for the delaying or pre- vention of the progression from IGT to Type 2 diabetes.
In a still further aspect, the present compounds are useful for the delaying or pre- vention of the progression from non-insulin requiring Type 2 diabetes to insulin requiring
Type 2 diabetes.
In another aspect, the present compounds reduce blood glucose and triglyceride levels and are accordingly useful for the treatment and/or prevention of ailments and disor- ders such as diabetes and/or obesity.
In still another aspect, the present compounds are useful for the treatment and/or prophylaxis of insulin resistance (Type 2 diabetes), impaired glucose tolerance, dyslipidemia, disorders related to Syndrome X such as hypertension, obesity, insulin resistance, hypergly- : caemia, atherosclerosis, hyperlipidemia, coronary artery disease, myocardial ischemia and other cardiovascular disorders.
In still another aspect, the present compounds are effective in decreasing apoptosis in mammalian cells such as beta cells of Islets of Langerhans.
In still another aspect, the present compounds are useful for the treatment of certain renal diseases including glomerulonephritis, glomerulosclerosis, nephrotic syndrome, hyper- tensive nephrosclerosis. :
In still another aspect, the present compounds may also be useful for improving cognitive functions in dementia, treating diabetic complications, psoriasis, polycystic ovarian syndrome (PCOS) and prevention and treatment of bone loss, e.g. osteoporosis.
The present compounds may also be administered in combination with one or more further pharmacologically active substances eg., selected from antiobesity agents, antidiabet- ics, antihypertensive agents, agents for the treatment and/or prevention of complications re- sulting from or associated with diabetes and agents for the treatment and/or prevention of : complications and disorders resulting from or associated with obesity.
Thus, in a further aspect of the invention the present compounds may be adminis- tered in combination with one or more antiobesity agents or appetite regulating agents.
Such agents may be selected from the group consisting of CART (cocaine am- phetamine regulated transcript) agonists, NPY (neuropeptide Y) antagonists, MC4 (melano- cortin 4) agonists, orexin antagonists, TNF (tumor necrosis factor) agonists, CRF (corticotro- pin releasing factor) agonists, CRF BP (corticotropin releasing factor binding protein) an- tagonists, urocortin agonists, p3 agonists, MSH (melanocyte-stimulating hormone) agonists,
MCH (melanocyte-concentrating hormone) antagonists, CCK (cholecystokinin) agonists, se- rotonin re-uptake inhibitors, serotonin and noradrenaline re-uptake inhibitors, mixed sero- tonin and noradrenergic compounds, SHT (serotonin) agonists, bombesin agonists, galanin antagonists, growth hormone, growth hormone releasing compounds, TRH (thyreotropin re- leasing hormone) agonists, UCP 2 or 3 (uncoupling protein 2 or 3) modulators, leptin ago- nists, DA agonists (bromocriptin, doprexin), lipase/amylase inhibitors, RXR (retinoid X recep- tor) modulators or TR § agonists.
In one embodiment of the invention the antiobesity agent is leptin.
In another embadiment the antiobesity agent is dexamphetamine or amphetamine.
In another embodiment the antiobesity agent is fenfluramine or dexfenfluramine.
In stilt another embodiment the antiobesity agent is sibutramine.
In a further embodiment the antiobesity agent is orlistat. in another embodiment the antiobesity agent is mazindol or phentermine.
Suitable antidiabetics comprise insulin, GLP-1 (glucagon like peptide-1) derivatives such as those disclosed in WO 98/08871 to Novo Nordisk A/S, which is incorporated herein by reference as well as orally active hypoglycaemic agents.
The orally active hypoglycaemic agents preferably comprise suiphonylureas, bigua- nides, meglitinides, glucosidase inhibitors, glucagon antagonists such as those disclosed in
WO 99/01423 to Novo Nordisk A/S and Agouron Pharmaceuticals, Inc., GLP-1 agonists, po- tassium channel openers such as those disclosed in WO 97/26265 and WO 99/03861 to
Novo Nordisk A/S which are incorporated herein by reference, DPP-IV (dipeptidyl peptidase-
IV) inhibitors, inhibitors of hepatic enzymes involved in stimulation of gluconeogenesis and/or . glycogenolysis, glucose uptake modulators, compounds modifying the lipid metabolism such as antihyperlipidemic agents and antilipidemic agents as HMG CoA inhibitors (statins), com- pounds lowering food intake, RXR agonists and agents acting on the ATP-dependent potas- sium channel of the B-cells.
In one embodiment of the invention the present compounds are administered in ’ combination with insulin. in a further embodiment the present compounds are administered in combination with a sulphonylurea eg. tolbutamide, glibenclamide, glipizide or glicazide.
In another embodiment the present compounds are administered in combination with a biguanide eg. metformin.
In yet another embodiment the present compounds are administered in combination with a meglitinide eg. repaglinide or senaglinide.
In a further embodiment the present compounds are administered in combination with an a-glucosidase inhibitor eg. miglitol or acarbose.
In another embodiment the present compounds are administered in combination with an agent acting on the ATP-dependent potassium channel of the B-cells eg. tolbutamide, glibenclamide, glipizide, glicazide or repaglinide.
Furthermore, the present compounds may be administered in combination with nateglinide.
In still another embodiment the present compounds are administered in combination with an antihyperipidemic agent or antilipidemic agent eg. cholestyramine, colestipol, clofi- ’ brate, gemfibrozil, lovastatin, pravastatin, simvastatin, probucol or dextrothyroxine.
In a further embodiment the present compounds are administered in combination with more than one of the above-mentioned compounds eg. in combination with a sulphony- lurea and metformin, a sulphonylurea and acarbose, repaglinide and metformin, insulin and a ’ sulphonylurea, insulin and metformin, insulin, insulin and lovastatin, etc.
Furthermore, the present compounds may be administered in combination with one or more antihypertensive agents. Examples of antihypertensive agents are p-blockers such as alprenolol, atenolol, timolol, pindolol, propranolol and metoprolol, ACE (angiotensin con- verting enzyme) inhibitors such as benazepril, captopril, enalapril, fosinopril, lisinopril, quinapril and ramipril, calcium channel blockers such as nifedipine, felodipine, nicardipine, isradipine, nimodipine, diltiazem and verapamil, and a-blockers such as doxazosin, urapidil, prazosin and terazosin. Further reference can be made to Remington: The Science and
Practice of Pharmacy, 19" Edition, Gennaro, Ed., Mack Publishing Co., Easton, PA, 1995.
It should be understood that any suitable combination of the compounds according to the invention with one or more of the above-mentioned compounds -and optionally one or more further pharmacologically active substances are considered to be within the scope of the present invention. :
The present invention also relates to a process for the preparation of the above said novel compounds, their derivatives, their analogs, their tautomeric forms, their stereoisom- ers, their polymorphs, their pharmaceutically acceptable salts or pharmaceutically acceptable solvates.
PHARMACEUTICAL COMPOSITIONS
The compounds of the invention may be administered alone or in combination with . pharmaceutically acceptable carriers or excipients, in either single or multiple doses. The pharmaceutical compositions according to the invention may be formulated with phar- maceutically acceptable carriers or diluents as well as any other known adjuvants and ex- cipients in accordance with conventional techniques such as those disclosed in Remington:
The Science and Practice of Pharmacy, 19® Edition, Gennaro, Ed., Mack Publishing Co.,
Easton, PA, 1995. The compositions may appear in conventional forms, for example capsules, tablets, aerosols, solutions, suspensions or topical applications.
Typical compositions include a compound of formula | or a pharmaceutically acceptable acid addition salt thereof, associated with a pharmaceutically acceptable excipient which may be a carrier or a diluent or be diluted by a carrier, or enclosed within a carrier which can be in the form of a capsule, sachet, paper or other container. In making the compositions, conventional techniques for the preparation of pharmaceutical compositions may be used. For example, the active compound will usually be mixed with a carrier, or diluted by a carrier, or enclosed within a carrier which may be in the form of a ampoule, capsule, sachet, paper, or other container. When the carrier serves as a diluent, it may be ) solid, semi-solid, or liquid material which acts as a vehicle, excipient, or medium for the active compound. The active compound can be adsorbed on a granular solid container for example in a sachet. Some examples of suitable carriers are water, salt solutions, alcohols, polyethylene glycols, polyhydroxyethoxylated castor oil, peanut oil, olive oil, gelatine, lactose, terra alba, sucrose, cyclodextrin, amylose, magnesium stearate, talc, gelatin, agar, pectin, acacia, stearic acid or lower alkyl ethers of cellulose, silicic acid, fatty acids, fatty acid amines, fatty acid monoglycerides and diglycerides, pentaerythritol fatty acid esters, polyoxyethylene, hydroxymethylcellulose and polyvinyipyrrolidone. Similarly, the carrier or diluent may include any sustained release material known in the art, such as glyceryl monostearate or glyceryl distearate, alone or mixed with a wax. The formulations may also include wetting agents, emulsifying and suspending agents, preserving agents, sweetening agents or flavouring agents. The formulations of the invention may be formulated so as to provide quick, sustained, or delayed release of the active ingredient after administration to the patient by employing procedures well known in the art.
The pharmaceutical compositions can be sterilized and mixed, if desired, with auxil- iary agents, emulsifiers, salt for influencing osmotic pressure, buffers and/or colouring sub- stances and the like, which do not deleteriously react with the active compounds.
The route of administration may be any route, which effectively transports the active compound to the appropriate or desired site of action, such as oral, nasal, pulmonary, trans- dermal or parenteral e.g. rectal, depot, subcutaneous, intravenous, intraurethral, intramuscu- lar, intranasal, ophthalmic solution or an ointment, the oral route being preferred.
If a solid carrier is used for oral administration, the preparation may be tabletted, placed in a hard gelatin capsule in powder or pellet form or it can be in the form of a troche or lozenge. If a liquid carrier is used, the preparation may be in the form of a syrup, emulsion, soft gelatin capsule or sterile injectable liquid such as an aqueous or non-aqueous liquid suspension or solution.
For nasal administration, the preparation may contain a compound of formula dissolved or suspended in a liquid carrier, in particular an aqueous carrier, for aerosol application. The carrier may contain additives such as solubilizing agents, e.g. propylene glycol, surfactants, absorption enhancers such as lecithin (phosphatidyicholine) or cyclodextrin, or preservatives such as parabenes.
For parenteral application, particularly suitable are injectable solutions or suspen- sions, preferably aqueous solutions with the active compound dissolved in polyhydroxylated castor oil. : Tablets, dragees, or capsules having talc and/or a carbohydrate carrier or binder or the like are particularly suitable for oral application. Preferable carriers for tablets, dragees, or capsules include lactose, corn starch, and/or potato starch. A syrup or elixir can be used in cases where a sweetened vehicle can be employed.
A typical tablet which may be prepared by conventional tabletting techniques may contain: . Core:
Active compound (as free compound or salt thereof) 5 mg
Colloidal silicon dioxide (Aerosil) 1.5mg
Cellulose, microcryst. (Avicel) 70 mg
Modified cellulose gum (Ac-Di-Sol) 7.5mg "Magnesium stearate Ad.
Coating:
HPMC approx. 9 mg *Mywacett 9-40 T approx. 0.9 mg *Acylated monoglyceride used as plasticizer for film coating.
If desired, the pharmaceutical composition of the invention may comprise the compound of formula (I) in combination with further pharmacologically active substances such as those described in the foregoing.
The compounds of the invention may be administered to a mammal, especially a human in need of such treatment, prevention, elimination, alleviation or amelioration of diseases related to the regulation of blood sugar.
Such mammals include also animals, both domestic animals, e.g. household pets, and non-domestic animals such as wildlife.
The compounds of the invention are effective over a wide dosage range. A typical oral dosage is in the range of from about 0.001 to about 100 mg/kg body weight per day, preferably from about 0.01 to about 50 mg/kg body weight per day, and more preferred from about 0.05 to about 10 mg/kg body weight per day administered in one or more dosages such as 1 to 3 dosages. The exact dosage will depend upon the frequency and mode of ad- ministration, the sex, age, weight and general condition of the subject treated, the nature and severity of the condition treated and any concomitant diseases to be treated and other fac- tors evident to those skilled in the art. ’ The formulations may conveniently be presented in unit dosage form by methods known to those skilled in the art. A typical unit dosage form for oral administration one or more times per day such as 1 to 3 times per day may contain of from 0.05 to about 1000 mg, preferably from about 0.1 to about 500 mg, and more preferred from about 0.5 mg to about 200 mg.
Any novel feature or combination of features described herein is considered essential to this invention.
The present invention is further illustrated in the following representative examples which are, however, not intended to limit the scope of the invention in any way.
EXAMPLES . "The compounds used as starting materials are either known compounds or com- pounds which can readily be prepared by methods known per se. The structures of the com- pounds are confirmed by either elemental analysis (MA) nuclear magnetic resonance (NMR), mass spectrometry (MS) or optical rotation. NMR shifts (3) are given in parts per million (ppm) and only selected peaks are given. mp is melting point and is given in °C. Column chromatography was carried out using the technique described by W.C. Still et al, J. Org.
Chem. 1978, 43, 2923-2925 on Merck silica gel 60 (Art 9385). The optical rotation was -measured on a Advanced Laser Polarimeter.
The abbreviations as used in the examples have the following meaning:
THF: tetrahydrofuran
DMSO: dimethylsulfoxide
CDCl;: deutorated chloroform
DMF: N,N-dimethylformamide min: minutes h: hours
General procedure (A)
Step A:
Reacting a compound of formula lI - ~~ © (n) wherein X and Y are defined as above, through a Wittig-like process with for example (Et0),PO(CHR,)COORs (Wherein Rg is an alkyl group), in the presence of a base such as sodium hydride, EtONa and the like to give a compound of formula lll
X Y
0
R;
Oo {0} wherein X, Y, R; and R; are defined as above :
Step B:
Reducing the compound of formula Ili, wherein X, Y, Ry and Rg are defined as above with a suitable reagent such as diisobutylaluminium hydride, to give a compound of formula IV
X Y
Be
OH av) wherein X, Y and R, are defined as above, and
StepC:
Reacting the compound of formula IV, wherein X, Y and R, are defined as above, (except that when X or Y is substituted with hydroxy, amino, Cys-alkylamino or Cp¢- dialkylamino these functionalities have to be protected) with a compound of formula V z M “Ar
N° . o.
Re wherein Z, Ar, Q and R; are defined as above, except that R; is not hydrogen under Mitsun- obu conditions, using a reagent such as triphenylphosphine/diethylazodicarboxylate and the like to obtain a compound of formula {, wherein X, Y, Z, Ar, Q, R, and Rp are defined as above, except that R; is not hydrogen.
General procedure (B)
Step A:
Converting the -OH functionality in the compound of formula IV, wherein X, Y and R; are defined as above, to an appropriate leaving group (L) such as p-toluenesulfonate, methanesulfonate, halogen (for example by methods according to: Houben-Weyl, Methoden der organischen Chemie, Alkohole Iii, 6/1b, Thieme-Verlag 1984, 4th Ed., pp. 927-939;
Comprehensive Organic Transformations. A guide to functional group preparations, VCH
Publishers 1989, 1% Ed., pp. 353-363 and J. Org. Chem. ,Vol. 36 (20), 3044-3045, 1971), triflate and the like, to give a compound of formula Vi Co
X Y
L vi) wherein X, Y, Ry and L are defined as above.
Step B:
Reacting the compound of formula VI wherein L is a leaving group such as p- toluenesulfonate, methanesulfonate, halogen, triflate and the like and wherein X, Y and R, are defined as above with a compound of formula V wherein Z, Ar, Q and R; are defined as above, except that R; is not hydrogen to give a compound of formula | wherein XY, Z Ar Q,
R, and R,are defined as above, except that R, is not hydrogen.
General procedure (C)
Step A: : . By chemical or enzymatic saponification of a compound of formula | wherein X,Y, Z,
Ar, Q, R, and R, are defined as above, except that R; is not hydrogen to give a compound of formula l wherein X, Y, Z, Ar, Q, R, and R; are defined as above, except that R, is hydrogen. - Example 1 (General procedure (A)) 3-{3-{3,3-Bis-(4-bromo-phenyl)-allyloxyl-phenyl}-propionic acid ethyl ester “CL - ) 0] . 8
CH,
StepA :
A solution of triethyl phosphonoacetate (26.8 g, 120.0 mmol) in dry THF (100 mL) was added at 0°C over a period of 25 min. to a stirred suspension of sodium hydride (60% in oil, 4.8 g, 120.0 mmol) in dry THF (100 ml). After stirring at 0°C for 30 min. a solution of 4,4'-
dibromobenzophenone (20.4 g, 60.0 mmol) in dry THF (200 ml) was added and the mixture slowly warmed to room temperature, and stirring continued for 48 h. The reaction mixture was diluted with1N hydrochloric acid (400 ml) and ethyl acetate (100 mi). The organic phase was separated, and the aqueous phase further extracted with ethyl acetate (2 x 300 ml). The combined organic phases were washed with water (300 ml x 3), dried (MgSQ,), filtered and concentrated in vacuo. The product was purified by column chromatography on silica gel (15% ethyl acetate in n-heptane eluent) to give 24.5 g (99%) 3,3-bis-(4-bromophenyl)-acrylic acid ethyl ester as an off-white amorphous solid. 'H NMR (CDCLa): 61.15 (3H, t), 4.05 (2H, q), 6.34 (1H, s), 7.10 (4H, dd), 7.48 (4H, dd).
Step B:
A 1M solution of DIBAL-H in toluene (150 ml, 150 mmol) was added dropwise, at — 70°C over 30 min, to a stirred solution of 3,3-bis-(4-bromophenyl)-acrylic acid ethyl ester (24.5 g, 59.7 mmol) in dry THF (400 ml) and stirred for 30 min. The mixture was warmed to room temperature, and stirred for 1.5 h. The mixture was poured into 1N HCI (700 ml) with vigorous stirring and the product extracted with ethyl acetate (3 x 200 ml). The combined or- ganic extracts were washed with brine, dried (MgSO,), and evaporated to give the crude } product as an off-white solid, which was purified by column chromatography on silica gel (15% ethyl acetate in n-heptane eluent). The purified product was diluted in boiling heptane, filtered and the filtrate cooled, giving 15.8 g (72%) 3,3-bis-(4-bromophenyl)prop-2-en-1-ol as an crystalline solid. 'H NMR (CDCL,): 61.45 (1H, t), 4.18 (2H, t), 6.23 (1H, t), 7.06 (4H, dd), 7.45 (4H, dd).
Step C: 1) To an ice-cooled solution of 3-(3-hydroxyphenyl)propionic acid (20.0 g, 120 mmol) in ethanol was dropwise added thionyl chloride (8.8 ml, 120 mmol). The mixture was stirred at room temperature over night, concentrated in vacuo and submitted to flash chroma- tography (10% ethyl acetate in toluene eluent) to give 23.3 g of 3-(3-hydroxy-phenyl)- propionic acid ethyl ester. .
TH NMR (CDCLs): 61.25 (3H, 1), 2.60 (2H, t), 2.88 (2H, t), 4.13 (2H, q), 6.65-6.75 (3H, m), 7.05-7.15 (1H, m). 2) Under a atmosphere of nitrogen, azodicarboxylic dipiperidide (567 mg, 2.25 mmol) was added at 0-5°C to a stirred solution of tributylphosphine (455 mg, 2.25 mmol), 3- (3-hydroxy-phenyl)-propionic acid ethyl este (291 mg, 1.5 mmol) and 3,3-bis-(4- promophenyl)prop-2-en-1-ol (552 mg, 1.5 mmol) in dry THF (15 ml), the mixture warmed to room temperature, and stirred for 48 h. The reaction mixture was concentrated in vacuo, and added water and ethyl acetate (30 mi each). The aqueous layer was collected and further extracted with ethyl acetate (2 x 30 ml). The organic layers were combined, washed with wa- ter, dried (MgSO,) and evaporated. The crude product was then purified by column chroma- tography on silica (toluene eluent) to give 756 mg (93%) of the title compound. 'H NMR (CDCLy): 61.23 (3H, t), 2.57 (2H, t), 2.88 (2H, t), 4.10 (2H, q), 4.52 (2H, d), 6.30 (1H, t), 6.62-6.70 (2H, m), 6.77 (1H, d), 7.03-7.18 (5H, m), 7.48 (2H, d), 7.52 (2H, d).
Example 2 (General procedure (C)) 3-{3-[3,3-Bis~(4-bromo-pheny)-allyloxy}-phenyi}-propionic acid
Br ® 0) Br had 3-{3-[3,3-Bis-(4-bromo-phenyl)-allyloxy}-phenyl}-propionic acid ethyl ester (example 1) (755 mg, 1.4 mmol) was hydrolysed in 1N NaOH (5.6 ml) and ethanol (15 mi) for 16 h at room temperature. Water (5 ml) was added and ethanol removed by concentratio in vacuo.
The mixture was neutralised with 6N HCI. The crude product was extracted with ethyl acetate (x 3) The organic layers were combined, dried (MgSQO4) and evaporated. The residue was dissolved in toluene and the title compound precipitated with petroleum ether, to give 430 mg of the title compound.
HNMR (MeOD): §2.55 (2H, t), 2.85 (2H, t), 4.55 (2H, d), 6.35 (1H, t); 6.60-6.73 (2H, m), 6.78 (1H, d), 7.08-7.18 (5H, m), 7.45 (2H, d), 7.58 (2H, d).
Example 3 (General procedure (A)) 3-{3-[3,3-Bis-(4-bromo-phenyl)-allyloxy]-phenyl}-acetic acid ethyl ester
Br ® 7) Br ( 6] 0]
Step A-B: 3,3-Bis-(4-bromophenyl)prop-2-en-1-ol was prepared as described in example 1, step A-B.
Step C: 1) To an ice-cooled solution of 3-(3-hydroxyphenyl)-acetic acid (21.0 g, 138 mmal) in ethanol was dropwise added thiony! chloride (10.1 ml. 138 mmol). The mixture was stirred at room temperature over night, concentrated in vacuo and submitted to flash chromatography (10% ethyl acetate in toluene eluent) to give 23.8 g of 3-(3-hydroxy-phenyl)-acetic acid ethyl ester. 'H NMR (CDCL,): 61.27 (3H, 1), 3.55 (2H, s), 4.15 (2H, q), 6.11 (1H, s), 6.68-6.85 (3H, m), 7.15 (1H, 1). 2) Under a atmosphere of nitrogen, azodicarboxylic dipiperidide (567 mg, 2.25 mmol) was added at 0-5°C to a stirred solution of tributylphosphine (455 mg, 2.25 mmol), 3- (3-hydroxy-phenyl)-acetic acid ethyl este (270 mg, 1.5 mmol) and 3,3-bis-(4- bromophenyl)prop-2-en-1-ol (552 mg, 1.5 mmol) in dry THF (15 ml), the mixture warmed to room temperature, and stirred for 48 h. The reaction mixture was concentrated in vacuo, and added water and ethyl acetate (30 ml each). The aqueous layer was collected and further extracted with ethyl acetate (2 x 30 ml). The organic layers were combined, washed with wa- ter, dried (MgSQ,) and evaporated. The crude product was then purified by column chroma- tography on silica (toluene eluent) to give 701 mg (88%) of the title compound. 'H NMR (CDCLs): 51.23 (3H, t), 3.53 (2H, s), 4.13 (2H, q), 4.52 (2H, d), 6.32 (1H, t), 6.70- 6.78 (2H, m), 6.87 (1H, d), 7.05-7.13 (5H, m), 7.20 (2H, t), 7.42 (2H, d), 7.52 (2H, d).
Example 4 (General procedure (C)) 3-{3-[3,3-Bis~(4-bromo-phenyl)-allyloxy]-phenyl}-acetic acid
Br< 3 g Br oO Oo
JT
StepA:
The title compound was prepared from 3-{3-[3,3-bis-(4-bromo-phenyi)-allyloxy}- phenyl}-acetic acid ethyl ester (example 3) (701 mg, 1.3 mmol) by a procedure analogous to that described in example 2. 'H NMR (CDCL,): 53.55 (2H, s), 4.53 (2H, d), 6.30 (1H, t), 6.75 (2H, bs), 6.84 (1H, d), 7.10 (4H, 1), 7.20 (1H, t), 7.40 (2H, d), 7.52 (2H, d).
Example 5 (General procedure (A)) 3-{4-[3,3-Bis-(4-bromo-phenyi)-allyloxy]-phenyl}-propionic acid ethyl ester oe 0) oO
Step A-B: 3,3-Bis-(4-bromophenyl)prop-2-en-1-ol was prepared as described in example 1 step A-B.
Step C.
1) To an ice-cooled solution of 3-(p-hydroxyphenyl)-propionic acid (8.3 g, 50.0 mmol) in ethanol (100 mL) was dropwise added thiony! chloride (3.7 mL, 50.7 mmol). The mixture was stirred at room temperature over night, concentrated in vacuo and the residue purified by kugelrohr distillation, to give 9.6 g (99%) of 3-(4-hydroxy-phenyl)-propionic acid ethyl ester as a colourless oil. 'H NMR (CDCLs): 61.21 (3H, t), 2.58 (2H, t), 2.86 (2H, t), 4.12 (2H, q), 6.75 (2H, d), 6.90 (1H, bs), 7.01 (2H, d). 2) Under a atmosphere of nitrogen, azodicarboxylic dipiperidide (504 mg, 2.0 mmol) was added at 0-5°C to a stirred solution of tributyiphosphine (404 mg, 2.0 mmol), 3-(4- hydroxy-phenyl)-propionic acid ethyl ester (388 mg, 2.0 mmol) and 3,3-bis-(4- bromophenyl)prop-2-en-1-ol (736 mg, 2.0 mmol) in dry THF (50 ml), the mixture warmed to room temperature, and stirred for 4 h. The reaction mixture was concentrated in vacuo, and added water and ethyl acetate (75 ml each). The aqueous layer was collected and further extracted with ethyl acetate (2 x 75 ml). The organic layers were combined, washed with wa- ter, dried (MgSO,) and evaporated. The crude product was then purified by column chroma- tography on silica (25 % ethylacetane in heptane eluent) to give 1.0 g (92%) of the title com- pound. 'H NMR (CDCLs): § 1.23 (3H, t), 2.58 (2H, t), 2.88 (2H, t), 4.12 (2H, 9), 4.52 (2H, d), 6.32 (1H, 1), 6.76 (2H, d), 7.04-7.15 (6H, m), 7.42 (2H, d), 7.53 (2H, d). } Example 6 (General procedure (C)) 3-{4-[3,3-Bis-(4-bromo-phenyl)-allyloxy]-phenyl}-propionic acid pel 0]
To 0
Step A
To a solution of 3-{4-[3,3-bis-(4-bromo-phenyl)-allyloxy]-phenyl}-propionic acid ethyl ester (example 5) (1.0 g, 2.0 mmol) in toluene (20 mL) and ethanol (50 mL) was added 1N
NaOH (10.0 mL) and the reaction mixture was stirred for 16 h at room temperature. The re- action mixture was concentrated in vacuo and 1N HCl added. The product was extracted with ethyl acetate (x 3). The organic layers were combined, washed with water, dried (MgSO), filtered and concentrated in vacuo. The residue was recrystalised from warm etha- nol (100 mL), witch was concentrated to 60 mL, and cooled, to give 600 mg (56 %) of the title compound. 'H NMR (CDCl): 62.65 (2H, 1), 2.90 (2H, t), 4.53 (2H, d), 6.32 (1H, t), 6.76 (2H, d), 7.03-7.15 (6H, m), 7.42 (2H, d), 5.52 (2H, d).
Example 7 (General procedure (A)) {4-[3,3-Bis-(4-bromo-phenyl)-allyloxyl-phenyl}-acetic acid methyl ester : @} 0]
A,
Step A-B: 3,3-Bis-(4-bromophenyl)prop-2-en-1-ol was prepared as described in example 1 step A-B.
Step C:
Under a atmosphere of nitrogen, azodicarboxylic dipiperidide.(504 mg, 2.0 mmol) was added at 0-5°C to a stirred solution of tributylphosphine (404 mg, 2.0 mmol), methyl 4- hydroxyphenylacetate (250 mg, 1.5 mmol) and 3,3-bis-(4-bromophenyl)prop-2-en-1-ol (552 mg, 1.5 mmol) in dry THF (10 ml), the mixture stirred for 1 h, filtered and concentrated in vacuo. The crude product was then purified by column chromatography on silica (toluene eluent). The purified product was suspended in petroleum ether, filtered to give 480 mg (62%) of the title compound.
'H NMR (CDCL,): 53.55 (2H, s), 3.68 (3H, 5), 4.52 (2H, d), 6.32 (1H, 1), 6.78 (2H, d), 7.03- 7.20 (6H, m), 7.42 (2H, d), 7.53 (2H, d).
Example 8 (General procedure (C)) {4-[3,3-Bis-(4-bromo-phenyl)-allyloxy]-phenyl}-acetic acid 6)
Tr
OH
Step A
To a solution of {4-[3,3-bis-(4-bromo-phenyl)-allyloxy]-phenyl}-acetic acid ethyl ester (example 7) (473 mg, 0.9 mmol) in THF (5 mL) and ethanol (3 mL) was added 1N NaOH (3 "10 mL) and the reaction mixture was stirred at 60°C for 1 h and at room temperature over night.
The title compound as an sodium salt, was isolated by filtration and washed with ethanol to give 375 mg (81 %). 'H NMR (MeOD): 63.40 (2H, s), 4.53 (2H, d), 6.35 (1H, t), 6.73 (2H, d), 7.08-7.25 (6H, m), 7.47 (2H, d), 5.57 (2H, d).
Example 9 (General procedure (A)) {4-13,3-Bis-(4-bromo-phenyl)-allyloxy]-3-chioro-phenyl}-acetic acid ethyl ester
Br } : g Br
Cl 0)
CL
Iq
Step A-B: 3,3-Bis-(4-bromophenyl)prop-2-en-1-ol was prepared as described in example 1 step A-B.
StepC: 1) To an ice-cooled solution of 3-chloro-4-hydroxyphenylacetic acid (10.0 g, 53.0 mmol) in ethanol was dropwise added thionyl chloride (3.9 ml, 53.5 mmol). The mixture was stirred at room temperature for 48 h, concentrated in vacuo and submitted to flash chroma- tography (graduated from toluene to 5% ethyl acetate in toluene eluent) to give 11.0 g of 3- chloro-4-hydroxyphenylacetic acid ethyl ester. 'H NMR (CDCL,): 51.27 (3H, t), 3.53 (2H, s), 4.15 (2H, q), 5.65 (1H, s), 6.95 (1H, d), 7.08 (1H, dd), 7.26 (1H, d). . 2) A solution of tributylphosphine (955 ul, 3.0 mmol), 3- chloro-4- hydroxyphenylacetic acid ethyl ester (472 mg, 2.2 mmol) and 3,3-bis-(4-bromophenyl)prop-2- en-1-0l (736 mg, 2.0 mmol) in dry THF (15 ml) was stirred at 0-5°C for 30 min, under a at- mosphere of nitrogen. Azodicarboxylic dipiperidide (756 mg, 3.0 mmol) was added the mix- ’ ture stirred at 0-5°C for 2 h, and at room temperature over night. The reaction mixture was filtered and the filtrate concentrated in vacuo. The crude product was then purified by column chromatography on silica (eluent graduated from heptane to toluene) to give 1.0 g (89%) of the title compound. . 'H NMR (CDCL3): 61.25 (3H, t), 3.52 (2H, s), 4.14 (2H, q), 4.58 (2H, d), 6.34 (1H, 1), 6.72 (1H, d), 7.03-7.14 (5H, m), 7.30 (1H, d), 7.42 (2H, d), 7.53 (2H, d).
Example 10 (General procedure (C)) {4-[3,3-Bis-(4-bromo-phenyi)-allyloxyl-3-chloro-phenyi}-acetic acid
Cl oO
OH
Step A:
To a solution of {4-3,3-bis-(4-bromo-phenyl)-allyloxy]-3-chloro-phenyl}-acetic acid ethyl ester (example 9) (1.0 g, 1.8 mmol) in THF (8 ml) and ethanol (5 ml) was added 1N
NaOH (4.0 ml) and the reaction mixture was stirred for 1 h at room temperature. The reaction mixture was concentrated in vacuo. The residue was suspended in water and 817 mg (82%) of the title compound was isolated by filtration as the sodium salt. 'H NMR (MeOD): §3.37 (2H, 5), 4.57 (2H, d), 6.40 (1H, t), 6.79 (1H, d), 7.07-7.20 (5H, m), 7.35 (1H, d), 7.45 (2H, d), 7.58 (2H, d).
Example 11 (General procedure (A)) (E)-{4-[3-(4-Bromo-phenyl)-3-phenyi-allyloxy]-phenyl}-acetic acid methyl ester “CL = . 0] 0]
QPS
Sodium (5.29 g, 230 mmol) was added to ethanol (200 ml) at 20°C and the mixture stirred until the metal had fully reacted. Triethyl phosphonoacetate (30.7 mi, 153 mmol) was © added, the mixture stirred for 20 min, then a solution ef 4-bromobenzophenone (20.0 g, 76.6 mmol) was added and the reaction mixture heated to 70°C under reflux for 17 h. The solution was cooled, the ethanol evaporated and the residue partitioned between 4 N HCI and ethy! acetate. The aqueous layer was collected and further extracted with ethyl acetate (2 x 200 ml). The organic layers were combined, washed with brine, dried (MgSO,) and evaporated.
This was purified by column chromatography on silica gel to give: (Z)-3-(4-bromophenyl)-3-phenylacrylicacid ethyl ester as a white crystalline compound; 11.1 g. *H NMR (300 MHz, CDCl,) & 1.17 (3H, t), 4.07 (2H, q), 6.37 (1H, s), 7.08 (2H, d), 7.20- 7.42 (5H, m), 7.50 (2H, d); and N (E)-3-(4-bromophenyl)-3-phenylacrylicacid ethy! ester as a clear oil; 12.0 g. NMR (300 MHz,
CDCly) 8: 1.10 (3H, 1), 4.05 (2H, q), 6.34 (1H, 5), 7.10-7.22 (4H, m), 7.34-7.48 (5H, m).
Step B:
A 1.2 M solution of DIBAL-H in toluene (45 mi, 42 mmol) was added dropwise, at — 15°C over 20 min, to a stirred solution of (E)-3-(4-bromophenyl)-3-phenylacrylicacid ethyl es- ter (6.0 g, 18.1 mmol) in dry THF (80 mi), and the mixture stirred for 30 min. Rochelles salt and water was carefully added, and the resulting mixture extracted with ethyl acetate (x2).
The combined organic extracts were washed with brine, dried (MgSO,), and evaporated to give 5.2 g of (E)-3-(4-bromo-phenyi)-3-phenyl-prop-2-en-1-ol. 'H NMR (300 MHz, CDCly) & 1.40 (1H, brs), 4.22 (2H, d), 6.23 (1H, t), 7.06-7.18 (4H, m), 7.32-7.45 (5H, m).
Step C:
Azodicarboxylic dipiperidide (0.756 g, 3.0 mmol) was added at 0-5°C {o a stirred so- lution of tributylphosphine (0.94 ml, 786 mg, 3.0 mmol), methyl 4-hydroxyphenylacetate (332 mg, 2.0 mmol) and (E)-3-(4-bromo-phenyl)-3-phenyl-prop-2-en-1-ol (578 mg, 2.0 mmol) in dry THF (25 mi), the mixture was stirred for 1h. The mixture was filtered and concentrated vacuo. The residue was purified by flash chromatography on silica gel (toluene as eluent) to give 710 mg (81%) of the title compound. 'H NMR (300 MHz, CDCl) & 3.54 (2H, s), 3.67 (3H, s), 4.55 (2H, d), 6.30 (1H, 1), 6.78 (2H, d), 7.10-7.22 (6H, m), 7.35-7.43 (5H, m).
Example 12 (General procedure (C)) (E)-{4-[3-(4-Bromo-phenyl)-3-phenyl-allyloxy]-phenyl}-acetic acid
CL -
ROU
OH
Step A:
To a solution of (E)~{4-[3-(4-bromo-phenyl)-3-phenyl-allyloxy]-phenyl}-acetic acid ethyl ester (example 11) (700 mg, 1.6 mmol) in THF (5 m) and ethanol (5 mi) was added 1N
NaOH (5.0 ml) and the reaction mixture was stirred for 1 h at 60°C for 1h and at room tem-
perature over night. The reaction mixture was added water and the organic solvent evapo- rated. 1 N HCI was added to pH ~1-2 and the product extracted with dichloro- methanefisopropanol (19:1). The combined organic phases were dried (MgSO), filtered and concentrated in vacuo. The residue was suspended in toluene/petroleum ether (1:1) and 490 mg (70%) of the title compound was isolated by filtration. 'H NMR (CDCl): 63.57 (2H, s), 4.5 (2H, d), 6.30 (1H, 1), 6.79 (2H, d), 7.08-7.22 (6H, m), 7.35-7.45 (5H, m).
Example 13 (General procedure (A)) (2)-{4-[3-(4-Bromo-phenyl)-3-phenyl-allyloxyl-phenyl}-acetic acid methyl ester
CL - ’ 0] 0)
Th
Step A: (2)-3-(4-bromophenyl)-3-phenylacrylicacid ethyl ester was prepared as described in example 11 step A.
A 1.2 M solution of DIBAL-H in toluene (84 ml, 100 mmol) was added dropwise, at — 15°C over 20 min, to a stirred solution of (Z)-3-(4-bromophenyl)-3-phenylacrylicacid ethyl es- ter (11.1 g, 33.5 mmol) in dry THF (150 ml), and the mixture stirred for 30 min. Rochelles salt and water was carefully added, and the resulting mixture extracted with ethyl acetate (x2).
The combined organic extracts were washed with brine, dried (MgSO), and evaporated to give 9.3 g of (2)-3-(4-bromo-phenyl)-3-phenyl-prop-2-en-1-ol. 'H NMR (300 MHz, CDCl) & 1.40 (1H, brs), 4.22 (2H, d), 6.23 (1H, 1), 7.06-7.18 (4H, m), 7.32-7.45 (5H, m).
Step C:
Azodicarboxylic dipiperidide (0.756 g, 3.0 mmol) was added at 0-5°C to a stirred so- lution of tributylphosphine (0.94 ml, 786 mg, 3.0 mmol), methyl 4-hydroxyphenylacetate (332 mg, 2.0 mmol) and (Z)-3-(4-bromo-phenyl)-3-phenyl-prop-2-en-1-ol (578 mg, 2.0 mmol) in dry THF (25 ml), the mixture was stirred for 1h. The mixture was filtered and concentrated vacuo. The residue was purified by flash chromatography on silica gel (toluene as eluent) to give 650 mg (74%) of the title compound. 'H NMR (300 MHz, CDCl) & 3.55 (2H, s), 3.68 (3H, s), 4.54 (2H, d), 6.33 (1H, 1), 6.80 (2H, d), 7.10 (2H, d), 7.16 (2H, d), 7.20-7.32 (5H, m), 7.53 (2H, d). :
Example 14 (General procedure (A)) (E)-{4-[3-(4-Bromo-phenyl)-3-phenyl-allyloxy]-3-chloro-phenyi}-acetic acid ethyl ester
TL =
Cl oN
Step A-B: (E)-3-(4-Bromo-phenyl)-3-phenyl-prop-2-en-1-ol was prepared as described in ex- : ample 11 step a-b.
Step C: 1) To an ice-cooled solution of 3-chloro-4-hydroxyphenyl-acetic acid (10.0 g, 53 mmol) in ethanol was dropwise added thionyl chloride (3.9 mL. 53.5 mmol). The mixture was stirred at room temperature over night, concentrated in vacuo and submitted to flash chroma- tography (eluent: graduated from 10 % ethyl acetate in toluene to toluen) to give 11 g of 3- chloro-4-hydroxyphenyl-acetic acid ethyl ester. .
TH NMR (CDCL,): 51.25 (3H, t), 3.52 (2H, s), 4.15 (2H, q), 5.75 (1H, s), 6.93 (1H, d), 7.05 (1H, d), 7.25 (1H, s). 2) Under a atmosphere of nitrogen, azodicarboxylic dipiperidide (756 mg, 3.0 mmol) was added at 0-5°C to a stirred solution of tributylphosphine (786 mg, 3.0 mmol), 3-chloro-4-
hydroxyphenyl-acetic acid ethyl ester (537 mg, 2.5 mmol) and (E)-3-(4-bromo-phenyl)-3- phenyl-prop-2-en-1-ol (578 mg, 2.0 mmol) in dry THF (15 ml), the mixture was stirred for 2 h.
The reaction mixture was filtered and concentrated in vacuo. The residue was purified by flash chromatography on silica (eluent: toluen) to give 640 mg (66%) of the title compound.
HNMR (CDCLs): 61.25 (3H, t), 3.50 (2H, 5), 4.14 (2H, q), 4.53 (2H, d), 6.33 (1H, 1), 6.70 (1H, d), 7.03 (1H, dd), 7.13 (2H, d), 7.15-7.22 (2H, m), 7.30 (1H, d), 7.35-7.45 (5H, m).
Example 15 (General procedure (C)) (E)-{4-[3-(4-Bromo-phenyl)-3-phenyl-allyloxy]-3-chloro-phenyi}-acetic acid ne! &
Cl 0] “10 OH
Step A
The title compound was prepared from (E)-{4-{3-(4-bromo-phenyl)-3-phenyl- allyloxy]-3-chloro-phenyl}-acetic acid ethyl ester (example 14) (640 mg, 1.3 mmol) by a pro- cedure analogous to that described in example 12.
HNMR (CDCLs): 63.53 (2H, s), 4.63 (2H, d), 6.33 (1H, t), 6.68 (1H, d), 7.03 (1H, dd), 7.08- 7.22 (4H, m), 7.30 (1H, d), 7.35-7.45 (5H, m).
Example 16 (General procedure (A)) (E){4-[3-(9H-Fluoren-2-yl)-but-2-enyloxy}-phenyl}-acetic acid methyl ester
( 0) 0 109
Step A; (E)-{4-[3-(9H-Fluoren-2-yl)}-but-2-enyloxy}-phenyl}-acetic acid methyl ester was pre- pared from 2-acetylfluorene and triethylphosphonoacetate by a procedure analogous to that described in example 11-A. : "MH NMR (CDCL,): 61.32 (3H, t), 2.63 (3H, s), 3.90 (2H, s), 4.23 (2H, q), 6.22 (2H, d}, 7.28- 7.42 (4H, m), 7.54 (4H, dt), 7.68 (2H, d), 7.78 (4H, 1).
Step B:
A 1M solution of DIBAL-H in toluene (15 ml, 15 mmol) was added dropwise, at — 70°C over 30 min, to a stirred solution of (E)-{4-[3-(SH-fluoren-2-yl)-but-2-enyloxy]-phenyl}- acetic acid methyl ester (2.0 g, 7.2 mmol) in dry THF (100 ml) and stirred for 30 min. The mixture was warmed to room temperature, and stirred for 1.5 h. The mixture quenched with methanol (2 mL), added 1N HCI (30 ml) and the product extracted with ethyl acetate (3 x 50 ml). The combined organic extracts were washed with brine, dried (MgSQO.), and evaporated to give the crude (E)-3-(9H-fluoren-2-yl)-but-2-en-1-ol. :
TH NMR (CDCLs): 62.13 (3H, s), 3.90 (2H, s), 4.40 (2H, s), 6.05 (1H, 1), 7.22-7.42 (2H, m), 7.45 (1H, d), 7.54 (1H, d), 7.60 (1H, s), 7.75 (2H, dd)
Step C: ~ Undera atmosphere of nitrogen, methyl 4-hydroxyphenylacetate (183 mg, 1.1 mmol) was added to a stirred cooled solution of azodicarboxylic dipiperidide (378 mg, 1.5 mmol), tributylphosphine (304 mg, 1.5 mmol) and (E)-3-(3H-fluoren-2-yl)-but-2-en-1-ol (236 mg, 1.0 mmol) in dry benzene (30 ml), the mixture warmed to room temperature, and stirred for 17 h. The reaction mixture was diluted with water (100 ml) and ethyl acetate (100 ml each). The aqueous layer was collected and further extracted with ethyl acetate (2 x 50 ml).
The organic layers were combined, washed with brine, dried (MgSO) and evaporated. The crude product was then purified by column chromatography on silica (eluent: 15 % ethyl ace- tate in toluene) to give 240 mg (62%) of the title compound. 'H NMR (CDCL3): & 2.19 (3H, s), 3.58 (2H, s), 3.69 (3H, s), 3.90 (2H, s), 4.76 (2H, d), 6.11 (1H, t), 6.92 (2H, d), 7.21 (2H, d), 7.30 (1H, d), 7.37 (1H, 1), 7.45 (1H, d), 7.54 (1H, d), 7.62 (1H, s), 7.73 (2H, dd).
Example 17 (General procedure (C)) (E){4-[3-(9H-Fluoren-2-yl)-but-2-enyloxyl-phenyl}-acetic acid [
ROS!
OH
"10 Step A: (E)~{4-[3~(9H-Fluoren-2-yl)-but-2-enyloxy]-phenyi}-acetic acid ethyl ester (example 16) (193 mg, 0.5 mmol) was suspended in 1N NaOH (5.0 mL) and methanol (5 mL) and stirred for 16 h at room temperature. A 2" portion and 1N NaOH was added and stirring con- tinued for 24 h. The mixture was concentrated to 10 mL volume then diluted with 1N HCI (50 mL) and ethyl acetate (150 mL). The aqueous layer was separated and extracted with ethy! acetate (50 mL) The organic layers were combined, dried (NaSO,) and evaporated. The residue was recrystallised from ethyl acetate (50 ml) to give 140 mg (75 %) of the title com- pound as an pale yellow powder. 'H NMR (DMSO): §2.17 (3H, s), 3.49 (2H, s), 3.93 (2H, s), 4.78 (2H, d), 6.11 (1H, s), 6.94 (2H, d), 7.18 (2H, d), 7.31 (1H, dt), 7.38 (1H, t), 7.50 (1H, d), 7.58 (1H, d), 7.70 (1H, s), 7.87 (2H, 1).
Example 18 (General procedure (A)) (E)-{4-[3-(9H-Fluoren-2-yl)-but-2-enyloxy]-phenyl}-propionic acid ethyl ester
O
S oO
Step A-B: (E)-3-(9H-Fluoren-2-yl)-but-2-en-1-ol was prepared as described in example 16 step
A-B.
Step C:
The title compound was prepared from 3-(4-hydroxy-phenyl)-propionic acid ethyl es- ter (example 5, step C-1) (213 mg, 1.1 mmol) and (E)-3-(9H-fluoren-2-yl)-but-2-en-1-ol (235 mg, 1.0 mmol) by a procedure analogous to that described in example 16-step C. “10 'H NMR (CDCL,): 61.25 (3H, t), 2.18 (3H, s), 2.60 (2H, t), 2.90 (2H, 1), 3.90 (2H, s), 4.12 (2H, q), 4.75 (2H, d), 6.10 (1H, t), 6.89 (2H, d), 7.13 (2H, d), 7.30 (1H, d), 7.38 (1H, t), 7.45 (1H, d), 7.53 (1H, d), 7.63 (1H, s), 7.75 (2H, dd).
Example 19 (General procedure (C)) (E)-{4-[3-(9H-Fluoren-2-yl)-but-2-enyloxy]-phenyl}-propionic acid 0]
G
Step A; (E){4-[3-(9H-Fluoren-2-yl)-but-2-enyloxy}-phenyl}-propionic acid ethyl ester (exam- ple 18) (220 mg, 0.53 mmol) was suspended in 1N NaOH (5.5 mi) and methanol (20 ml) and stirred for 24 h at room temperature. The mixture was diluted with 1N HCI (50 ml) and ethyl acetate (50 mL). The aqueous layer was separated and extracted with ethyl acetate (50 ml)
The organic layers were combined, washed with brine, dried (MgSO,) and evaporated. The residue was recrystallised from boiling ethanol (20 ml) to give 150 mg (73 %) of the title compound. 'H NMR (DMSO): 52.16 (3H, s), 2.76 (2H, 1), 3.93 (2H, s), 4.76 (2H, d), 6.10 (1H, t), 6.91 (2H, d), 7.14 (2H, d), 7.28-7.40 (2H, m), 7.50 (1H, d), 7.58 (2H, d), 7.69 (1H, s), 7.87 (2H, t).
Example 20 (General procedure (A)) (E)-{4-{3-(4-Phenoxy-phenyl)-but-2-enyloxy]-phenyl}-acetic acid methyl ester
OO
CA
0”
Step A-C: ~The title compound was prepared from 4-phenoxyacetophenone (12.0 g, 0.056 mol) by a sequence analogous to that described in example 22 step A-C, to give 168 mg (44%) of the title compound 'H NMR (CDCL,): 62.12 (3H, s), 3.57 (2H, s), 3.68 (3H, 5), 4.72 (2H, d), 6.02 (1H, 1), 6.9-7.5 (13H, m). }
Example 21 (General procedure CH : : : : : (E)-{4-[3-(4-Phenoxy-phenyl)-but-2-enyloxy}-phenyl}-acetic acid -
) Oy 0
OU
OH
Step A: (E)-{4-[3-(4-Phenoxy-phenyl)-but-2-enyloxy]-phenyi}-acetic acid methyl ester (ex- ~ ample 20 (150 mg, 0.4 mmol) was suspended in 1N NaOH (1 mL) and ethanol (5 ml) and stirred for 24 h at room temperature. The mixture was diluted with 1N HCI (1 mL) and ethyl acetate (10 mL). The aqueous layer was separated and extracted with ethyl acetate (20 mL)
The organic layers were combined, washed with brine, dried (MgSO) and evaporated to give 116 mg (80 %) of the title compound. 'H NMR (DMSO): 62.10 (3H, s), 3.57 (2H, s), 4.74 (2H, d), 6.01 (1H, t), 6.9-7.2 (SH, m), 7.35-7.5 (4H, m).
Example 22 (General procedure (A)) (EX{3-[3-(4'-Bromo-biphenyl-4-yl)-but-2-enyloxy]-phenyl}-acetic acid ethyl ester 0) NG :
JY
Step A: (E)-3-(4'-Bromo-biphenyl-4-yl)-but-2-encic acid ethyl ester was prepared from 4-(4- bromophenyl)acetophenone (12.0 g, 0.044 mol), sodium (1.25 g, 0.052 mol) and triethyl phosphonoacetate (11.73 g, 0.052 mol) by a procedure analogous to that described in ex- ample 11 step A, yielding 11.97 g (80%).
'H NMR (300 MHz, CDCl) 8: 1.32 (3H, 1), 2.61 (3H, d), 4.23 (2H, q), 6.19 (1H, d), 7.40-7.58 (8H, m).
Step B: (E)-3-(4'-bromo-biphenyl-4-yl)-but-2-en-1-ol was prepared from (E)-3-(4'-bromo- biphenyl-4-yl)-but-2-enoic acid ethyl ester (3.45 g, 10.0 mmol) and DIBAL-H (1M in toluene, 40 mL, 40 mmol) by a procedure analogous to that described in example 11 step B, yielding 1.68 g (55%). 'H NMR (300MHz, CDCly) 3: 2.14 (3H, d), 4.4 (2H, t), 6.05 (1H, dt), 7.45-7.55 (8H, m).
Step C:
Under a atmosphere of nitrogen, azodicarboxylic dipiperidide (353 mg, 1.4 mmol) was added at 0-5 °C to a stirred solution of tributylphosphine (0.4 mL, 1.4 mmol), ethyl 3- hydroxyphenylacetate (120 mg, 0.7 mmol) and (E)- 3-(4'-bromo-biphenyl-4-yl)-but-2-en-1-ol (200 mg, 0.7 mmol) in dry THF (10 ml), the mixture stirred for 16 h, filtered and concentrated in vacuo. The crude product was then purified by column chromatography on silica (eluent: % ethyl acetate in heptane) to give 168 mg (44%) of the title compound. ’ HNMR (CDCLs): 61.25 (3H, t), 2.17 (3H, 8), 3.59 (2H, 5), 4.14 (2H, q) 4.77 (2H, d), 6.11 (1H, t), 6.85-8.90 (3H, m), 7.23 (1H, m), 7.45-7.57 (8H, m). 20 Example 23 (General procedure (C)) (E)-{3-[3-(4'-Bromo-biphenyl-4-yl)-but-2-enyloxy]-phenyl}-acetic acid “oy oO OH or
Step A: (E)-{3-[3-(4'-Bromo-biphenyl-4-yl)-but-2-enyloxy]-phenyl}-acetic acid ethyl ester (example 22) (150 mg, 0.32 mmol) was suspended in 1N NaOH (0.82 mL) and ethanol (5 mL) and stirred for 24 h at room temperature. The mixture was diluted with 1N HCI (0.82 mL) and ethyl acetate (10 mL). The aqueous layer was separated and extracted with ethyl ace- - tate (20 mL) The organic layers were combined, washed with brine, dried (MgSOQ,) and evaporated to give 138 mg (98 %) of the title compound. ‘HNMR (DMSO): 52.13 (3H, s), 3.54 (2H, s), 4.78 (2H, d), 6.12 (1H, t), 6.83-6.9 (3H, m), 7.23 (1H, m), 7.56-7.68 (8H, m).
Example 24 (General procedure (A)) (E)-{4-{3-(4'-Bromo-biphenyl-4-yi)-but-2-enyloxy]-phenyl}-acetic acid methy! ester
Br
Soy 0)
TC
0”
Step C:
Under an atmosphere of nitrogen, azodicarboxylic dipiperidide (353 mg, 1.4 mmol) was added at 0-5 °C to a stirred solution of tributylphosphine (0.4 mL, 1.4 mmol), methyl 4- hydroxyphenylacetate (110 mg, 0.7 mmol) and (E)- 4-(4'-Bromo-biphenyl-4-yf)-but-2-en-1-ol .15 (example 22 step A-B)(200 mg, 0.7 mmol) in dry THF (10 mL), the mixture stirred for 16 h, filtered and concentrated in vacuo. The crude product was then purified by column chroma- tography on silica (eluent: 20 % ethyl acetate in heptane) to give 264 mg (84%) of the title compound. 'H NMR (CDCL,): 62.12 (3H, s), 3.58 (2H, s), 3.68 (3H, s), 4.76 (2H, d), 6.12 (1H, 1), 6.8-6.9 : (3H, m), 7.23 (1H, m), 7.56-7.68 (8H, m).
Example 25 (General procedure (C)) (E)+{4-[3-(4'-Bromo-biphenyi-4-yf)-but-2-enyloxy]-phenyl}-acetic acid
Poy 0)
TL
OH
Step A: (E)~{4-[3-(4'-Bromo-biphenyl-4-yl)-but-2-enyloxy}-phenyl}-acetic acid ethyl ester (ex- ample 24) (210 mg, 0.58 mmol) was suspended in 1N NaOH (1.16 mL) and ethanol (5 mL) and stirred for 24 h at room temperature. The mixture was diluted with 1N HCI (1.16 mL) and ethyl acetate (10 mL). The aqueous layer was separated and extracted with ethyl acetate (30
L) The organic layers were combined, washed with brine, dried (MgSQ,) and evaporated to give 141 mg (55 %) of the title compound. . 'H NMR (DMSO): 62.14 (3H, s), 3.53 (2H, s), 4.78 (2H, d), 6.10 (1H, t), 6.86.9 (3H, m), 7.23 (1H, m), 7.53-7.72 (8H, m).
Example 26 (General procedure (A)) (E){3-Chloro-4-[3-(4-fluoro-phenyl)-3-(2-phenyl-thiazol-5-yl)-allyloxyl-phenyl}-acetic acid ethyl ester ] ~S
N ) —
Cl 0] 1081 a 0
Step A-C:
The title compound was prepared by a method analogous to that described in ex- ample 14, using (4-fluorophenyl)-(2-phenyl-1,3-thiazol-5-yl)-methanone as starting material. 'H NMR (CDCL,): 51.25 (3H, 1), 3.52 (2H, s), 4.15 (2H, q), 4.53 (2H, d), 6.40 (1H, t), 6.70 (1H, d), 7.03-7.20 (3H, m), 7.24-7.38 (4H, m), 7.40-7.48 (3H, m), 7.93 (2H, dd).
Example 27 (General procedure (C)) (E){3-Chloro-4-{3-(4-fluoro-phenyl)-3-(2-phenyl-thiazol-5-yl)-allyloxy]-phenyl}-acetic acid ] ~S nN =
Cl
Oo oN
OH
Step A:
The title compound was prepared by a method analogous to that described in ex- ample 2, using (E)-{3-chloro-4-[3-(4-fluoro-phenyl)-3-(2-phenyi-thiazol-5-yl)-allyloxy}-phenyl}- acetic acid ethyl ester (example 26) as starting material. 'H NMR (MeOD): 53.50 (2H, s), 5.53 (2H, d), 6.43 (1H, t), 6.78 (1H, d}, 7.08 (1H, dd), 7.13- 7.23 (2H, m), 7.25-7.38 (4H, m), 7.40-7.50 (3H, m), 7.85-7.95 (2H, m).
Example 28 (General procedure (A)) (2)+3-Chloro-4-[3-(4-fluoro-phenyl)-3-(2-phenyl-thiazol-5-yl)-allyloxy]-phenyl}-acetic acid ethyl ester )
F S
NS N
Cl 0 o>
Step A-C:
The title compound was prepared by a method analogous to that described in ex- ample 14, using (4-fluorophenyl)-(2-phenyl-1 ,3-thiazol-5-yl)-methanone as starting material.
HNMR (CDCl): 61.25 (3H, 1), 3.52 (2H, s), 4.15 (2H, q), 4.85 (2H, d), 6.35 (1H, 1), 6.84 (1H, d), 7.0-7.18 (3H, m), 7.28-7.40 (4H, m), 7.40-7.48 (3H, m), 7.90-7.98 (2H, m).
Example 29 (General procedure (9) (E)~{3-Chloro-4-{3-(4-fluoro-phenyl)-3-(2-phenyl-thiazol-5-yi)-allyloxy]-phenyi}-acetic acid
F S
J N
Cl 0 08
OH
Step A:
The title compound was prepared by a method analogous to that described in ex- ample 2, using (2)-{3-chloro-4-[3-(4-fluoro-phenyl)-3-(2-phenyl-thiazol-5-yl)-allyloxy]-phenyl}- acetic acid ethyl ester (example 28) as starting material.
'H NMR (MeOD): 63.53 (2H, s), 6.40 (1H, t), 6.98 (1H, d), 7.03-7.25 (3H, m), 7.28-7.50 (7H, m), 7.88-7.95 (2H, m).
Example 30 (General procedure (A)) (E)-{3-Chloro-4-{3-(2-phenyl-thiazol-5-yl)-but-2-enyloxy]-phenyl}-acetic acid ethyl ester ~S
N
=
Cl 0] 0 o>
Step A-C:
The title compound was prepared by a method analogous to that described in ex- ample 14, using 1-(2-phenyi-thiazol-5-yl)-ethanone as starting material. "HNMR (CDCLs): 61.25 (3H, t), 2.19 (3H, s), 3.52 (2H, s), 4.15 (2H, q), 4.78 (2H, d), 6.17 (1H, 1), 6.90 (1H, d), 7.15 (1H, d), 7.34 (1H, 5), 7.38-7.48 (3H, m}), 7.75 (1H, s), 7.88-7.80 (2H, m).
Example 31 (General procedure (C)) (E)-{3-Chloro-4-[3-(2-phenyl-thiazol-5-yl)-but-2-enyloxy]-phenyl}-acetic acid
~S
N ==
Cl 0
OH
Step A:
The title compound was prepared by a method analogous to that described in ex- ample 2, using (E)-{3-chloro-4-[3-(2-phenyl-thiazol-5-yl)-but-2-enyloxy}-phenyl}-acetic acid ethyl ester (example 30) as starting material. *H NMR (CDCL;): 62.18 (3H, s), 3.55 (2H, 5), 4.78 (2H, d), 6.15 (1H, t), 6.90 (1H, d), 7.13 (1H, dd), 7.33 (1H, d), 7.38-7.47 (3H, m), 7.79 (1H, s), 7.85-7.93 (2H, m).
Example 32 (General procedure (A)) (2)-{3-Chioro-4-[3-(2-phenyl-thiazol-5-yl)-but-2-enyloxyl-phenyl}-acetic acid ethyl ester
PT
NN N
Cl 0 : 0] 0™
Step A-C:
The title compound was prepared by a method analogous to that described in ex- ample 14, using 1-(2-phenyl-thiazol-5-yl)-ethanone as starting material.
'H NMR (CDCLs): £1.25 (3H, t), 2.25 (3H, s), 3.52 (2H, 5), 4.15 (2H, q), 4.80 (2H, d), 5.95 (1H, t), 6.82 (1H, d), 7.10 (1H, dd), 7.32 (1H, d), 7.40-7.50 (3H, m), 7.75 (1H, s), 7.90-7.98 (2H, m).
Example 33 (General procedure (CC) (£)3-Chloro-4-[3-(2-phenyl-thiazol-5-yl)-but-2-enyloxy]-phenyl}-acetic acid
F Ss
J N
Cl 0 08! - OH
Step A:
The title compound was prepared by a method analogous fo that described in ex- ample 2, using (2){3-chloro-4-[3-(2-phenyl-thiazol-5-yl)-but-2-enyloxy]-phenyl}-acetic acid ethyl ester (example 32) as starting material. 'H NMR (CDCL,): 52.25 (3H, s), 3.55 (2H, s), 4.79 (2H, d), 5.96 (1H, 1), 6.83 (1H, d), 7.12 (1H, dd), 7.32 (1H, d), 7.40-7.50 (3H, m), 7.79 (1H, s), 7.88-7.97 (2H, m).
Example 34 (General procedure (A)) (E)-{4-[3-Biphenyl-4-yl-3-(2-phenyl-thiazol-5-yl)-allyloxy]-3-chloro-phenyl}-acetic acid ethyl ester g —
Cl
TL 1 0 o>
Step A-C:
The title compound was prepared by a method analogous to that described in ex- ample 14, using (1,1 -biphenyl)-4-yl-(2-phenyl-1,3-thiazol-5-yl)-methanone as starting mate- rial 'H NMR (CDCLy): 51.25 (3H, t), 3.52 (2H, 5), 4.15 (2H, q), 4.63 (2H, d), 6.43 (1H, t), 6.75 (1H, d), 7.15 (1H, dd), 7.30 (1H, d), 7.35-7.54 (9H, m), 7.64-7.70 (4H, m), 7.88-7.98 (2H, m).
Example 35 (General procedure (C)) (E){4-[3-Biphenyl-4-yl-3-(2-phenyl-thiazol-5-yl)-allyloxy]-3-chloro-phenyl}-acetic acid 72 : J =
Cl
OL 1 0]
OH
Step A:
The title compound was prepared by a method analogous to that described in ex- ample 2, using (E)-{4-{3-Biphenyl-4-yl-3-(2-phenyl-thiazol-5-yl)-allyloxy]-3-chloro-phenyl}- acetic acid ethyl ester (example 34) as starting material.
'H NMR (CDCLj): 6 3.54 (2H, s), 4.63 (2H, d), 6.42 (1H, t), 6.73 (1H, d), 7.15 (1H, dd), 7.32 (1H, dd), 7.35-7.53 (9H, m), 7.62-7.79 (4H, m), 7.87-7.93 (2H, m).
Example 36 (General procedure (A)) (2){4-[3-Biphenyl-4-yl-3-(2-phenyl-thiazol-5-yl)-allyloxy]-3-chioro-phenyl}-acetic acid ethyl ester .
PT
NS N
Cl 6]
LL
- o>
Step A-C:
The title compound was prepared by a method analogous to that described in ex- ample 14, using (1,1 -biphenyl)-4-yl-(2-phenyl-1,3-thiazol-5-yl)-methanone as starting mate- rial. 'H NMR (CDCL3): 51.25 (3H, t), 3.52 (2H, s), 4.15 (2H, q), 4.87 (2H, d), 6.44 (1H, t), 6.85 (1H, d), 7.09 (1H, dd), 7.32 (1H, d), /.37 (1H, d), 7.40-7.52 (8H, m), 7.53-7.65 (4H, m), 7.90- 7.98 (2H, m).
Example 37 (General procedure (C)) (Z)-{4-[3-Biphenyl-4-yl-3-(2-phenyl-thiazol-5-yl)-allyloxy}-3-chloro-phenyi}-acetic acid
SU +
Na N
Cl 0
TLL
OH
Step A:
The title compound was prepared by a method analogous to that described in ex- ample 2, using (Z)-{4-[3-Biphenyl-4-yl-3-(2-phenyl-thiazol-5-yl)-allyloxy}-3-chloro-phenyi}- acetic acid ethyl ester (example 36) as starting material. 'H NMR (CDCLs): 63.55 (2H, s), 4.88 (2H, d), 6.44 (1H, 1), 6.87 (1H, d), 7.12 (1H, dd), 7.32 (1H, d), 7.35 (1H, d), 7.40-7.50 (7H, m), 7.55-7.65 (4H, m), 7.82 (1H, s), 7.90-7.87 (2H, m).
PHARMACOLOGICAL METHODS
Invitro PPARalpha, PPARgamma and PPARdelta activation activity
The PPAR transient transactivation assays are based on transient transfection into human HEK293 cells of two plasmids encoding a chimeric test protein and a reporter protein respectively. The chimeric test protein is a fusion of the DNA binding domain (DBD) from the yeast GAL4 transcription factor to the ligand binding domain (LBD) of the human PPAR pro- teins. The PPAR-LBD moiety harbored in addition to the ligand binding pocket also the na- tive activation domain (activating function 2 = AF2) allowing the fusion protein to function as a PPAR ligand dependent transcription factor. The GAL4 DBD will direct the chimeric protein to bind only to Gal4 enhancers (of which none existed in HEK293 cells). The reporter plas- mid contained a Gal4 enhancer driving the expression of the firefly luciferase protein. After transfection, HEK293 cells expressed the GAL4-DBD-PPAR-LBD fusion protein. The fusion protein will in turn bind to the Gal4 enhancer controlling the luciferase expression, and do nothing in the absence of ligand. Upon addition to the cells of a PPAR ligand luciferase pro- tein will be produced in amounts corresponding to the activation of the PPAR protein. The amount of luciferase protein is measured by light emission after addition of the appropriate
Substrate.
CELL CULTURE AND TRANSFECTION
HEK293 cells were grown in DMEM + 10% FCS. Cells were seeded in 96-well plates the day before transfection to give a confluency of 50-80 % at transfection. A total of 0,8 ng DNA containing 0,64 ug pM1a/yLBD, 0,1 ng pCMVBGal, 0,08 ug pGL2(Gal4)s and 0,02 ug pADVANTAGE was transfected per well using FuGene transfection reagent accord- ing to the manufacturers instructions (Roche). Cells were allowed to express protein for 48 h followed by addition of compound.
Plasmids: Human PPAR a, y and § was obtained by PCR amplification using cDNA synthe- sized by reverse transcription of MRNA from human liver, adipose tissue and plancenta re- spectively. Amplified cDNAs were cloned into pCR2.1 and sequenced. The ligand binding domain (LBD) of each PPAR isoform was generated by PCR (PPAR: aa 167 - C-terminus;
PPARYy: aa 165 - C-terminus; PPARS: aa 128 — C-terminus) and fused to the DNA binding domain (DBD) of the yeast transcription factor GAL4 by subcloning fragments in frame into the vector pM1 (Sadowski et al. (1992), Gene 118, 137) generating the plasmids pM1aLBD, pM1yLBD and pM13. Ensuing fusions were verified by sequencing. The reporter was con- : structed by inserting an oligonucleotide encoding five repeats of the GAL4 recognition se- quence (5 x CGGAGTACTGTCCTCCG(AG)) (Webster et al. (1988), Nucleic Acids Res. 16, 8192) into the vector pGL2 promotor (Promega) generating the plasmid pGL2(GAL4)s. pCMVBGal was purchased from Clontech and pADVANTAGE was purchased from Promega.
IN VITRO TRANSACTIVATION ASSAY
Compounds: All compounds were dissolved in DMSO and diluted 1:1000 upon addition to the cells. Compounds were tested in quadruple in concentrations ranging from 0.001 to 300 pM. Cells were treated with compound for 24 h followed by luciferase assay. Each compound was tested in at least two separate experiments.
Luciferase assay: Medium including test compound was aspirated and 100 pl PBS incl. 1mM Mg++ and Ca++ was added to each well. The luciferase assay was performed using the LucLite kit according to the manufacturers instructions (Packard Instruments). Light : emission was quantified by counting on a Packard LumiCounter. To measure 3- galactosidase activity 25 ul supematant from each transfection lysate was transferred to a new microplate. B-galactosidase assays were performed in the microwell plates using a kit from Promega and read in a Labsystems Ascent Multiscan reader. The B-galactosidase data : were used to normalize (transfection efficiency, cell growth etc.) the luciferase data.
STATISTICAL METHODS
The activity of a compound is calculated as fold induction compared to an untreated sample. For each compound the efficacy (maximal activity) is given as a relative activity compared to to Wy14,643 for PPAR, Rosiglitazone for PPARy and Carbacyclin for PPARS.
The EC50 is the concentration giving 50% of maximal observed activity. EC50 values were calculated via non-linear regression using GraphPad PRISM 3.02 (GraphPad Software, San
Diego, Ca). The results were expressed as means + SD.

Claims (39)

1. A compound of formula (I) X Y A 0 “ar © "rR, wherein X is aryl, fluorenyl or heteroaryl each of which is optionally substituted with one or more substituents selected from » halogen, hydroxy, cyano, amino, Cyg-alkylamino, C,¢-dialkylamino, Cjs-cycloalkyl- amino or carboxy; or eo Cis-alkyl, Cjg-cycloalkyl, Cse-alkenyl, C,s-alkynyl, Cig-alkoxy, Cas-cycloalkoxy,
C1.e-alkylthio or C;4-cycloalkylthio each of which is optionally substituted with haio- gen; or « aryl, aryloxy, arylthio, acyl, aralkyl, aralkoxy, heteroaryl, heteroaralkyl, heteroaryloxy, heteroaralkoxy each of which is optionally substituted with halogen, perhalomethyl, perhalomethoxy or Cys-alkyl; and Y is aryl or heteroaryl each of which is optionally substituted with one or more substituents selected from » halogen, hydroxy, cyano, amino, Cys-alkylamino, C.s-dialkylamino, Css-cycloalkyl amino, carboxy ; or oe Cie-alkyl, Cse-cycloalkyl, C,e-alkenyl, C,¢-alkynyl, Cig-alkoxy, Css-cycloalkoxy, . Cie-alkylthio or C3¢-cycloalkylthio each of which is optionally substituted with halo- : gen; or * aryl, aryloxy, arylthio, acyl, aralkyl, aralkoxy, heteroaryl, heteroaralkyl, heteroaryloxy, heteroaralkoxy each of which is optionally substituted with halogen, perhalomethyl or perhalomethoxy; or Y is Cys-alkyl, Cas-cycloalkyl, Cas-alkenyl, Cog-alkynyl, C4 s-alkenynyl; and
Ar is arylene which is optionally substituted with one or more halogen; and ZisOorS; and Qis -(CH,),— wherein nis 0, 1, 2 or 3; and Ry is hydrogen or halogen; or
R. is Cq.s-alkyl, Cas-cycloalkyl, Cqs-alkoxy, Cs s-cycloalkoxy each of which is optionally sub- stituted with one or more substituents selected from halogen, hydroxy, carboxy, amino or cyano; and Rs is hydrogen, Cqs-alkyl, Csg-cycloalkyl, C,.e-alkenyl, C,¢-alkynyl, Cye-alkenynyi or aryl; provided that X and Y independently is not a pyridine ring; or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable solvate thereof, ’ or any tautomeric forms, stereoisomers, mixture of stereoisomers including a racemic mix- ture, or polymorphs.
2. A compound according to claim 1 wherein X is aryl, fluorenyl or heteroaryl each of which is optionally substituted with one or more substituents selected from + halogen; or : e Cyealkyl, Cys-alkoxy, or Cie-alkyithio each of which is optionally substituted with halogen; or : o aryl, aryloxy, arylthio, aralkyl, aralkoxy, heteroaryl, heteroaralkyl, heteroaryloxy or heteroaralkoxy each of which is optionally substituted with halogen, perhalomethyl, perhalomethoxy or C4_g-alkyl. -
3. Acompound according to claim 1 or 2 wherein X is aryl, fluorenyl or heteroaryl each of which is optionally substituted with one or more substituents selected from ¢ halogen; or o aryl, aryloxy or heteroaryl each of which is optionally substituted with halogen, perha- lomethyl, perhalomethoxy or Cq.s-alkyl.
4. A compound according to any one of the claims 1-3 wherein X is aryl, which is optionally substituted with one or more substituents selected from * halogen; or s aryl, aryloxy or heteroaryl each of which is optionally substituted with halogen, perha- lomethyi, perhalomethoxy or Cqs-alkyl.
5. A compound according to claim 4 wherein X is phenyl, which is optionally substituted with one or more substituents selected from bromine; or o phenyl or phenyloxy. .
6. A compound according to any one of the claims 1-3 wherein X is heteroaryl, which is op- tionally substituted with one or more substituents selected from « halogen; or » aryl or heteroaryl each of which is optionally substituted with halogen, perhalomethyl, perhalomethoxy or Cy-alkyl.
7. A compound according to claim 6 wherein X is heteroaryl, which is optionally substituted with aryl.
8. A compound according to claim 7 wherein X is thiazolyl, which is optionally substituted with phenyl.
9. A compound according to any one of the claims 1-3 wherein X is fluorenyl.
10. A compound according to any one of the preceding claims wherein Y is aryl or het- eroaryl each of which is optionally substituted with one or more substituents selected from ¢ halogen; or ’ ¢ Cisalkyl, Cis-alkoxy or Cy.-alkyithio each of which is optionally substituted with halo- gen; or o aryl, aryloxy, arylthio, aralkyl, aralkoxy, heteroaryl, heteroaralkyl, heteroaryloxy or het- eroaralkoxy each of which is optionally substituted with halogen, perhalomethyl, perhalomethoxy or C,_g-alkyl.
11. A compound according to claim 10 wherein Y is aryl or heteroaryl each of which is op- tionally substituted with one or more substituents selected from o halogen; or o Cisalkyl, or ¢ aryl or heteroaryl each of which is optionally substituted with halogen, perhalomethyl, perhalomethoxy or Cq.¢-alkyl.
12. A compound according to any one of the claims 10-11 wherein Y is aryl, which is op- tionally substituted with one or more halogens.
13. A compound according to claim 12 wherein Y is phenyl, which is optionaily substituted with one or more halogens.
14. A compound according to any one of the claims 10-11 wherein Y is heteroary!, which is optionally substituted with one or more halogens.
15. A compound according to any one of the preceding claims wherein Y is Cy.¢-alkyl.
16. A compound according to claim 15 wherein Y is methyl.
17. A compound according to any one of the preceding claims wherein Ar is arylene, which is optionally substituted with one or more halogens.
18. A compound according to claim 17 wherein Ar is phenylene, which is optionally substituted with one or more halogens.
18. A compound according to any one of the preceding claims wherein Z is O.
20. A compound according to any one of the preceding claims wherein nis 1 or 2.
21. A compound according to any one of the preceding claims wherein R, is hydrogen.
22. A compound according to any one of the preceding claims wherein R; is C4.-alkyl.
23. Acompound according to any one of the preceding claims wherein R; is C4.;-alkoxy.
24. A compound according to any one of the preceding claims wherein R; is hydrogen or C,. e-alkyl.
25. A campound according to claim 24 wherein R; is hydrogen, methyl or ethyl.
26. The compound according to any one of the preceding claims which is: 3{3-[3,3-Bls-(4-bromo-phenyi)-allyloxy]-phenyl}-propionic acid ethyl ester, 3+{33,3-Bis-(4-bromo-phenyl)-allyloxy]-phenyi}-propionic acid, 3-{3-[3,3-Bis-(4-bromo-phenyl)-allyloxy]-phenyl}-acetic acid ethyl ester, 3-{33,3-Bis-(4-bromo-phenyl)-allyloxy]-phenyl}-acetic acid, 3-{4{3,3-Bis-(4-bromo-phenyi)-allyloxy]-phenyl}-propionic acid ethyl ester, 3-{4[3,3-Bis-(4-bromo-phenyl)-altyloxy]-phenyl}-propionic acid, {4-[3,3-Bis-(4-bromo-phenyl)-allyloxy}-phenyl}-acetic acid methyl ester, {4-[3,3-Bis-(4-bromo-phenyl)-allyloxy]-phenyl}-acetic acid, {4-3,3-Bis-(4-bromo-phenyl)-allyloxy]-3-chloro-phenyl}-acetic acid ethyl ester, {4-3,3-Bis-(4-bromo-phenyl)-allyloxy]-3-chloro-phenyl}-acetic acid, ’ (E)<{4-[3-(4-Bromo-phenyl)-3-phenyl-allyloxy}-phenyl}-acetic acid methyi ester, (E)-{4-{3-(4-Bromo-phenyl}-3-phenyl-allyloxy]-phenyi}-acetic acid, (Z2){4{3-(4-Bromo-phenyl)-3-phenyl-allyloxy]-phenyl}-acetic acid methyl ester, (E){4-[{3-(4-Bromo-phenyl)-3-phenyl-allyloxy]-3-chloro-phenyl}-acetic acid ethyl ester, (E)-{4-[3-(4-Bromo-phenyl)-3-phenyl-allyloxy]-3-chloro-phenyl}-acetic acid, or a pharmaceutically acceptable salt thereof.
27. The compound according to any one of the preceding claims 1-25, which is: (E)-{4-[3-(9H-Fluoren-2-yl)-but-2-enyloxy]-phenyl}-acetic acid methyl ester, (E)-{4-[3-(9H-Fluoren-2-yl)-but-2-enyloxyl-phenyl}-acetic acid, (E)-{4-[3-(9H-Fluoren-2-yl)-but-2-enyloxy]-phenyl}-propionic acid ethyl! ester, (E){4-3-(9H-Fluoren-2-yl)-but-2-enyloxy]-phenyl}-propionic acid, or a pharmaceutically acceptable salt thereof.
28. The compound according to any one of the preceding claims 1-25, which is: (E)-{4-[3-(4-Phenoxy-phenyl)-but-2-enyloxy}-phenyl}-acetic acid methyl ester, (E)-{4-[3-(4-Phenoxy-phenyl)-but-2-enyloxy]-phenyl}-acetic acid, , (E){3-[3-(4'-Bromo-biphenyl-4-yl)-but-2-enyloxyl-phenyl}-acetic acid ethyl ester,
(E)-{3-[3-(4'-Bromo-biphenyl-4-yl)-but-2-enyloxy]-phenyl}-acetic acid, : (E)-{4-{3-(4'-Bromo-biphenyl-4-yl)-but-2-enyloxyl-phenyl}-acetic acid methyl ester, (E){4-[3-(4'-Bromo-biphenyl-4-yl)-but-2-enyloxy]-phenyl}-acetic acid, (E){3-Chloro-4-[3-(4-fluoro-phenyl)-3-(2-phenyl-thiazol-5-yl)-allyloxy]-pheny!}-acetic acid ) 5 ethyl ester, (E)~{3-Chloro-4-[3-(4-fluoro-phenyl)-3-(2-phenyl-thiazol-5-yl)-allyloxy}-phenyl}-acetic acid, (2)4{3-Chloro-4-[3-(4-fluoro-phenyl)-3-(2-phenyl-thiazol-5-yl)-allyloxy}-phenyl}-acetic acid ethyl ester, (E)-{3-Chloro-4-[3-(4-fluoro-phenyl)-3-(2-phenyl-thiazoi-5-yl)-allyloxyl-phenyl}-acetic acid, (E){3-Chloro-4-[3-(2-phenyl-thiazol-5-yl)-but-2-enyloxy}-phenyl}-acetic acid ethyl ester, (E)-{3-Chloro-4-{3-(2-phenyl-thiazol-5-yl)-but-2-enyloxy]-phenyi}-acetic acid, (2)-{3-Chloro-4-[3-(2-phenyl-thiazol-5-yl)-but-2-enyloxy]-phenyl}-acetic acid ethyl ester, (2){3-Chloro-4-[3-(2-phenyl-thiazol-5-yi)-but-2-enyloxyl-phenyi}-acetic acid, (E)-{4-[3-Biphenyl-4-yl-3-(2-phenyl-thiazol-5-yl)-allyloxy}-3-chlora-phenyl}-acetic acid ethyl ester, (E)-{4-[3-Biphenyl-4-yl-3-(2-phenyl-thiazol-5-yl)-allyloxy}-3-chloro-phenyl}-acetic acid, (2){4-[3-Biphenyl-4-yl-3-(2-phenyl-thiazol-5-yl)-allyloxy]-3-chloro-phenyl}-acetic acid ethyl ’ ester, (2){4-[3-Biphenyl-4-yl-3-(2-phenyl-thiazol-5-yi)-allyloxy]-3-chloro-phenyl}-acetic acid, or a pharmaceutically acceptable salt thereof.
29. The compound according to any one of the preceding claims 1-25, which is: {4-[3,3-Bis-~(4-fluoro-pheny!)-allyloxy}-phenyl}-acetic acid, {4-[3,3-Bis-(4-chloro-phenyl)-allyloxy]-phenyl}-acetic acid, {4-[3,3-Bis-(4-iodo-phenyi)-allyloxy]-phenyl}-acetic acid, {4-[3,3-Bis-(4-trifluoromethyl-phenyi)-allyloxyl-phenyl}-acetic acid, {4-[3,3-Bis-(4-cyano-phenyl)-allyloxyl-phenyl}-acetic acid, {4-[3,3-Bis-bipheny!)-4-yl-allyloxy}-phenyl}-acetic acid, : {4-3,3-Bis-(4-furan-2-yl-phenyl)-allyloxy]-phenyl}-acetic acid, {4-[3,3-Bis-(4-furan-3-yl-phenyl)-allyloxyl-phenyl}-acetic acid, {4-[3,3-Bis-(4-thiophen-2-yl-phenyf)-allyloxy]-phenyl}-acetic acid, {4-[3,3-Bis-(4-thiophen-3-yl-phenyl)-allyloxy]-phenyl}-acetic acid, {4-3,3-Bis-(4-fluoro-phenyl)-allyloxy}-3-chloro-phenyl}-acetic acid, {4-[3,3-Bis-(4-chloro-phenyl)-allyloxy]-3-chloro-phenyl}-acetic acid, {4-{3,3-Bis-(4-iodo-phenyl)-allyloxy]-3-chloro-phenyl}-acetic acid,
{4-[3,3-Bis-(4-trifluoromethyl-phenyl)-3-chloro-allyloxy]-phenyl}-acetic acid, {4-[3,3-Bis-(4-cyano-phenyl)-allyloxy]-3-chloro-phenyl}-acetic acid, {4-[3,3-Bis-hiphenyl)-4-yl-allyloxy]-3-chloro-phenyl}-acetic acid, {4-[3,3-Bis-(4-furan-2-yl-phenyl)-allyloxy]-3-chloro-phenyl}-acetic acid,
{4-[3,3-Bis-(4-furan-3-yl-phenyl)-allyloxy}-3-chloro-phenyl}-acetic acid, {4-[3,3-Bis-(4-thiophen-2-yl-phenyl)-allyloxy]-3-chloro-phenyl}-acetic acid, {4-[3,3-Bis-(4-thiophen-3-yl-phenyl)-allyloxy}-3-chloro-phenyl}-acetic acid, {4-13,3-Bis-(4-fluoro-phenyl)-allyloxy]-3-bromo-phenyl}-acetic acid, {4-13,3-Bis-(4-chlora-phenyl)-allyloxy]-3-bromo-phenyl}-acetic acid,
{43 3-Bis-(4-iodo-phenyl)-allyloxy]-3-bromo-phenyi}-acetic acid, {43,3-Bis-(4-trifluoromethyl-phenyl)-3-bromo-allyloxy]-phenyl}-acetic acid, {43,3-Bis-(4-cyano-phenyl)-allyloxy]-3-bromo-phenyl}-acetic acid, {443,3-Bis-biphenyl)-4-yl-allyloxy]-3-bromo-phenyl}-acetic acid, {4-]3,3-Bis-(4-furan-2-yl-phenyl)-allyloxy]-3-bromo-phenyl}-acetic acid,
{4-[3,3-Bis-(4-furan-3-yl-phenyl)-allyloxy]-3-bromo-phenyl}-acetic acid, {4-[3,3-Bis-(4-thiophen-2-yl-phenyi)-allyloxy]-3-bromo-phenyl}-acetic acid, {4-{3,3-Bis-(4-thiophen-3-yl-phenyl)-allyloxy]-3-bromo-phenyl}-acetic acid,
: {4-[3,3-Bis-(4-fluoro-phenyl)-allyloxy]-3-iodo-phenyl}-acetic acid, {4-[3,3-Bis~(4-chloro-phenyl)-allyloxy]-3-iodo-phenyl}-acetic acid,
{4-[3,3-Bis-(4-iodo-phenyl)-allyloxy]-3-iodo-phenyl}-acetic acid, {4-[3,3-Bis-(4-trifluoromethyl-phenyl)-3-iodo-allyloxyl-phenyi}-acetic acid, {4-[3,3-Bis-(4-cyano-phenyl)-allyloxy]-3-iodo-phenyl}-acetic acid, {4-[3,3-Bis-biphenyl)-4-yl-allyloxy}-3-iodo-phenyl}-acetic acid, {4-[3,3-Bis-(4-furan-2-yl-phenyl)-allyloxy]-3-iodo-phenyl}-acetic acid,
{4-[3,3-Bis-(4-furan-3-yl-phenyl)-allyloxy]-3-iodo-phenyl}-acetic acid, {4-[3,3-Bis-(4-thiophen-2-yl-phenyl)-allyloxy]-3-iodo-phenyl}-acetic acid, {4-{3,3-Bis-(4-thiophen-3-yl-phenyl)-allyloxy]-3-iodo-phenyl}-acetic acid, 3-{4-[3,3-Bis-(4-fluora-phenyl)-allyloxy]-phenyi}-propionic acid, . 3-{4-[3,3-Bis-(4-chloro-phenyl)-allyloxy]-phenyl}-propionic acid,
3-{43,3-Bis-(4-iodo-phenyl)-allyloxy]-phenyl}-propionic acid, 3-{4-[3,3-Bis-(4-trifluoromethyi-phenyl)-allyloxy}-phenyi}-propionic acid, 3-{4-[3,3-Bis-(4-cyano-phenyl)-allyloxy]-phenyl}-propionic acid, 3-(4-[3,3-Bis-biphenyl)-4-yl-allyloxy]-phenyl}-propionic acid, 3-{4-[3,3-Bis-(4-furan-2-yl-phenyl)-allyloxy]-phenyl}-propionic acid,
3-{4-[3,3-Bis~(4-furan-3-yl-phenyl)-allyloxy]-phenyl}-propionic acid,
3-{4-{3,3-Bis~(4~thiophen-2-yi-phenyl)-allyloxy]-phenyl}-propionic acid, 3-{4-[3,3-Bis-(4-thiophen-3-yl-phenyl)-allyloxy]-phenyl}-propionic acid, 3-{4-{3,3-Bis-~(4~fluoro-phenyl)-allyloxy]-3-chloro-phenyl}-propionic acid, 3~{4-[3,3-Bis-(4-chloro-phenyl)-allyloxy]-3-chloro-phenyl}-propionic acid,
3-{4-[3,3-Bis~{4-iodo-phenyl)-allyloxy]-3-chloro-phenyl}-propicnic acid, 3-{4-{3,3-Bis~(4-trifluoromethyl-phenyl)-3-chloro-allyloxyl-phenyl}-propionic acid, 3-{4-[3,3-Bis~(4-cyano-phenyl)-allyloxy]-3-chloro-phenyl}-propionic acid, 3-{4-[3,3-Bis-biphenyl)-4-yl-allyloxy}-3-chloro-phenyl}-propionic acid, 3-{4-{3,3-Bis-(4-furan-2-yl-phenyl)-allyloxy]-3-chloro-phenyl}-propionic acid,
3-{4-3,3-Bis-(4-furan-3-yl-phenyl)-allyloxy]-3-chloro-phenyl}-propionic acid, 3-{4-[3,3-Bis-(4-thiophen-2-yl-phenyl)-allyloxy}-3-chloro-phenyl}-propionic acid, 3-{4-[3,3-Bis~(4-thiophen-3-yl-phenyl)-allyloxy]-3-chloro-phenyl}-propionic acid,
3-{4-[3,3-Bis~(4-fluoro-phenyl)-allyloxy}-3-bromo-phenyl}-propionic acid, 3-{4-3,3-Bis~(4-chloro-phenyl)-allyloxy]-3-bromo-phenyl}-propionic acid,
3-{4-3,3-Bis-(4-iodo-phenyl)-allyloxy]-3-bromo-phenyl}-propionic acid, 3-{4-[3,3-Bis-(4-trifluoromethyl-phenyl)-3-bromo-allyloxyl-phenyl}-propionic acid, 3-{4-[3,3-Bis-(4-cyano-phenyl)-allyloxy}-3-bromo-phenyi}-propionic acid,
: 3-{4-[3,3-Bis-biphenyl)-4-yl-allyloxy]-3-bromo-phenyl}-propionic acid, 3-{4-{3,3-Bis-(4-furan-2-yl-phenyl)-allyloxy}-3-bromo-phenyl}-propionic acid,
3~{4-{3,3-Bis-(4-furan-3-yl-phenyl)-allyloxy]-3-bromo-phenyl}-propionic acid, 3-{4-[3,3-Bis~(4-thiophen-2-yl-phenyl)-allyloxy]-3-bromo-phenyl}-propionic acid, 3-{4-[3,3-Bis-(4-thiophen-3-yl-phenyl)-allyloxy]-3-bromo-phenyl}-propionic acid, 3-{4-[3,3-Bis-(4-fluoro-phenyl)-allyloxy]-3-iodo-phenyl}-propionic acid, 3-{4-3,3-Bis-(4-chloro-phenyl)-allyloxy}-3-iodo-phenyi}-propionic acid,
3-{4-[3,3-Bis-(4-iodo-phenyl)-allyloxy}-3-iodo-phenyl}-propionic acid, 3-{4-[3,3-Bis-(4-trifluoromethyl-phenyl)-3-iodo-allyloxy}-phenyl}-propionic acid, 3-{4-[3,3-Bis-(4-cyano-phenyl)-allyloxy]-3-iodo-phenyl}-propionic acid, 3-{4-[3,3-Bis-biphenyl)-4-yl-allyloxy]-3-iodo-phenyl}-propionic acid, - 3-{4-[3,3-Bis-(4-furan-2-yl-phenyi)-allyloxy}-3-iodo-phenyl}-propionic acid,
3-{4-{3,3-Bis-(4-furan-3-yl-phenyl)-allyloxy}-3-iodo-phenyl}-propionic acid, 3-{4-[3,3-Bis-(4-thiophen-2-yl-phenyl)-allyloxy}-3-iodo-phenyl}-propionic acid, 3-{4-[3,3-Bis-(4-thiophen-3-yl-phenyl)-allyloxy}-3-iodo-phenyl}-propionic acid, or a pharmaceutically acceptable salt thereof.
30. A compound according to any one of the preceding claims 1-29, which is a PPARS ago- nist.
31. A compound according to claim 30, which is a selective PPARS agonist.
5 .
32. The use of a compound according to any one of the preceding claims 1-31 as a phar- maceutical composition.
33. A pharmaceutical composition comprising, as an active ingredient, at least one compound according to any one of the preceding claims 1-31 together with one or more pharmaceutically acceptable carriers or excipients.
34. A pharmaceutical compasition according to claim 33 in unit dosage form, comprising from about 0.05 mg to about 1000 mg, preferably from about 0.1 to about 500 mg of and especially preferred from about 0.5 mg to about 200 mg per day of compound according to any one of the preceding claims 1-31. ’
35. A pharmaceutical composition for the treatment and/or prevention of conditions mediated by nuclear receptors, in particular the Peroxisome Proliferator-Activated Receptors (PPAR), the composition comprising a compound according to any one of the preceding claims 1-31 together with one or more pharmaceutically acceptable carriers or excipients.
36. A pharmaceutical composition for the treatment and/or prevention of type | diabetes, type Il diabetes, impaired glucose tolerance, insulin resistance or obesity comprising a compound according to any of the preceding claims 1-31 together with one or more pharmaceutically acceptable carriers or excipients.
37. A pharmaceutical composition according to any one of the claims 33-36 for oral, nasal, : transdermal, pulmonal, or parenteral administration.
38. Use of a compound according to any one of the preceding claims 1-31 for the preparation of a pharmaceutical composition for the treatment and/or prevention of conditions mediated by nuclear receptors, in particular the Peroxisome Proliferator-Activated Receptors (PPAR).
z 67
39. Use of a compound according to any one of the preceding claims 1-31 for the preparation of a pharmaceutical composition for the treatment and/or prevention of Type 1 diabetes, Type 2 diabetes, dyslipidemia, syndrome X (including the metabolic syndrome, i.e. impaired glucose tolerance, insulin resistance, hypertrigyceridaemia and/or obesity), cardiovascular diseases (including atherosclerosis) and hypercholesteremia. AMENDED SHEET
ZA200400161A 2001-07-30 2004-01-09 Novel vinyl carboxylic acid derivatives and their use as antidiabetics etc. ZA200400161B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DKPA200101154 2001-07-30

Publications (1)

Publication Number Publication Date
ZA200400161B true ZA200400161B (en) 2004-08-18

Family

ID=8160643

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200400161A ZA200400161B (en) 2001-07-30 2004-01-09 Novel vinyl carboxylic acid derivatives and their use as antidiabetics etc.

Country Status (15)

Country Link
EP (1) EP1414778A1 (en)
JP (1) JP2004536150A (en)
KR (1) KR20040019087A (en)
CN (1) CN1537093A (en)
BR (1) BR0211414A (en)
CA (1) CA2452665A1 (en)
CZ (1) CZ2004133A3 (en)
HU (1) HUP0401575A2 (en)
IL (1) IL159547A0 (en)
MX (1) MXPA04000891A (en)
NO (1) NO20040389L (en)
PL (1) PL366401A1 (en)
RU (1) RU2004105956A (en)
WO (1) WO2003011807A1 (en)
ZA (1) ZA200400161B (en)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2005109555A (en) 2002-09-05 2005-11-10 Ново Нордиск А/С (DK) NEW VINYL CARBOXYLIC ACID DERIVATIVES AND THEIR THERAPEUTIC APPLICATION
BR0315667A (en) * 2002-10-28 2005-09-06 Novo Nordisk As Compound, use of a compound, pharmaceutical composition, and method for treating
BR0315683A (en) * 2002-10-28 2005-08-30 Novo Nordisk As A compound, use thereof, pharmaceutical composition, and method for treating and / or preventing nuclear receptor mediated conditions and for treating and / or preventing type i diabetes, type ii diabetes, impaired glucose tolerance, resistance to insulin or obesity
ITRM20030305A1 (en) * 2003-06-20 2004-12-21 Sigma Tau Ind Farmaceuti PREPARATION OF NEW DERIVATIVES OF FENYL ACID OR PHENOXYKYL MONO AND DIACARBOXY USEFUL IN THE TREATMENT OF HYPERGLYCAEMIA AND TYPICAL HYPERTRIGLYCERIDEMIA OF TYPE II DIABETES.
ES2378435T3 (en) * 2003-09-19 2012-04-12 Janssen Pharmaceutica N.V. �? 4 - ((phenoxyalkyl) thio) -phenoxyacetic acids and the like
CN1882524B (en) * 2003-09-19 2011-06-08 詹森药业有限公司 4-((phenoxyalkyl)thio)-phenoxyacetic acids and analogs
US8053598B2 (en) 2004-05-05 2011-11-08 High Point Pharmaceuticals, Llc Compounds, their preparation and use
PT1942898E (en) 2005-09-14 2011-12-20 Takeda Pharmaceutical Dipeptidyl peptidase inhibitors for treating diabetes
JO3006B1 (en) 2005-09-14 2016-09-05 Janssen Pharmaceutica Nv Novel Lysine Salts of 4-((Phenoxy Alkyl)Thio)-Phenoxy Acetic Acid Derivatives
JP5122462B2 (en) 2005-09-16 2013-01-16 武田薬品工業株式会社 Dipeptidyl peptidase inhibitor
NZ568488A (en) 2005-12-22 2011-07-29 High Point Pharmaceuticals Llc Phenoxy acetic acids as PPAR delta activators
PE20080188A1 (en) 2006-04-18 2008-03-10 Janssen Pharmaceutica Nv DERIVATIVES OF BENZOAZEPINE-OXY-ACETIC ACID AS PPAR-DELTA AGONISTS USED TO INCREASE HDL-C, REDUCE LDL-C AND REDUCE CHOLESTEROL
KR100693132B1 (en) * 2006-06-23 2007-03-14 동해전장 주식회사 Relay operation checking device of junction box
TW200838536A (en) 2006-11-29 2008-10-01 Takeda Pharmaceutical Polymorphs of succinate salt of 2-[6-(3-amino-piperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-ylmethy]-4-fluor-benzonitrile and methods of use therefor
US20120168303A1 (en) * 2011-01-05 2012-07-05 Sueng-Nien Kao Salt water activated emergency lighting device
CN103467409B (en) * 2013-09-03 2015-01-07 浙江医药高等专科学校 Substituted tetrazole carboxylic acid compounds and application thereof
CN103467406B (en) * 2013-09-03 2014-12-17 浙江医药高等专科学校 Halogen-substituted tetrazole carboxylic acid compounds, and preparation method and application thereof
CN103467408B (en) * 2013-09-03 2015-01-21 浙江医药高等专科学校 Tetrazole carboxylic acid compounds and application thereof
CN103467405B (en) * 2013-09-03 2015-01-07 浙江医药高等专科学校 Tetrazole carboxylic acid compounds, and preparation method and application thereof
CN103467407B (en) * 2013-09-03 2015-04-22 浙江医药高等专科学校 Tetrazole carboxylic acid compounds and application thereof
IL300000A (en) * 2020-07-22 2023-03-01 Reneo Pharmaceuticals Inc Crystalline ppar-delta agonist
WO2023147309A1 (en) 2022-01-25 2023-08-03 Reneo Pharmaceuticals, Inc. Use of ppar-delta agonists in the treatment of disease

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0098690B1 (en) * 1982-06-14 1987-09-09 Takeda Chemical Industries, Ltd. Vinyl carboxylic acid derivatives, their production and use
AU2652397A (en) * 1996-05-13 1997-12-05 Nippon Shinyaku Co. Ltd. Substituted ethylene compounds and drugs
JP2002542218A (en) * 1999-04-20 2002-12-10 ノボ ノルディスク アクティーゼルスカブ New compounds, their manufacture and use
CN1396903A (en) * 2000-01-28 2003-02-12 诺沃挪第克公司 Novel compound, their preparation and use

Also Published As

Publication number Publication date
CA2452665A1 (en) 2003-02-13
BR0211414A (en) 2004-08-17
JP2004536150A (en) 2004-12-02
CZ2004133A3 (en) 2004-06-16
IL159547A0 (en) 2004-06-01
MXPA04000891A (en) 2004-05-21
WO2003011807A1 (en) 2003-02-13
RU2004105956A (en) 2005-03-27
PL366401A1 (en) 2005-01-24
KR20040019087A (en) 2004-03-04
CN1537093A (en) 2004-10-13
HUP0401575A2 (en) 2004-11-29
NO20040389L (en) 2004-01-29
EP1414778A1 (en) 2004-05-06

Similar Documents

Publication Publication Date Title
ZA200400161B (en) Novel vinyl carboxylic acid derivatives and their use as antidiabetics etc.
CA2462514A1 (en) Dicarboxylic acid derivatives, their preparation and therapeutical use
US20120046350A1 (en) Novel compounds, their preparation and use
JP4638229B2 (en) Novel vinyl carboxylic acid derivatives and their therapeutic use
EP1745014B1 (en) Novel compounds, their preparation and use
US7968723B2 (en) Compounds, their preparation and use
US6869967B2 (en) Peroxisome proliferator-activated receptor (PPAR) active vinyl carboxylic acid derivatives
WO2004056740A1 (en) Dicarboxylic acid derivatives as ppar-agonists
JP4708184B2 (en) Novel compounds, their preparation and use
WO2003011814A1 (en) Novel vinyl n-(2-benzoylphenyl)-l-tyrosine derivatives and their use as antidiabetics etc
EP1558571B1 (en) Novel compounds useful in treating ppar mediated diseases
US20050070583A1 (en) Novel compounds, their preparation and use
US7067530B2 (en) Compounds, their preparation and use
US7220877B2 (en) Compounds, their preparation and use
WO2003011834A1 (en) Novel vinyl n-(2-benzoylphenyl)-l-tyrosine derivatives and their use as antidiabetics etc
US7816385B2 (en) Dimeric dicarboxylic acid derivatives, their preparation and use
AU2002316815A1 (en) Novel vinyl carboxylic acid derivatives and their use as antidiabetics etc.
US20030055076A1 (en) Novel compounds, their preparation and use